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Background: The generic substitution scheme obliges pharmacies to offer patients the least 
expensive (usually generic) version of the prescribed medicine. In the presence of important 
medical reasons, prescribers can oppose substitution by making a note on the prescription. For 
reimbursable drugs with the doctor’s reservation on the prescription, the patient’s out-of-
pocket payment remains the same as if the substitution did take place. The positive price 
difference is then covered by the National Insurance Scheme. When it is the patient who 
objects the substitution (patient’s reservation), without the note from his/her doctor, it is the 
patient who has to pay the price difference him/herself. The level of doctors’ reservations 
varies a lot across different areas of use and single substances. The average reservation rate 
for all substances is at the level of 5%, but for some preparations it can reach as high as 40%, 
which has its implications on the private and public pharmaceutical expenditure.  
Objectives: To examine some of the non-medical reasons for variation in doctors’ reservation 
levels. In particular the relationships between variables such as price difference between the 
original and generic alternatives, pharmacy chains, level of centrality, type of pharmaceutical 
and the corresponding level of doctors’ reservations are being tested.  
Methods: Descriptive statistics and binominal logistic regression were used to analyze an 
extensive dataset covering monthly records of sales, reservation levels and prices for selected 
9 pharmaceutical substances dispensed from all Norwegian community pharmacies, 
aggregated on the level of municipalities and pharmacy chains, in 5 different periods. In 
addition a mini focus group with 6 general practitioners from Oslo area was also performed to 
obtain professional opinions about the hypotheses, as well as to capture observations and 
attitudes towards generic substitution and doctors’ role in the scheme. 
Results: The hypothesis about the influence of price difference between generic and brand 
name preparations on doctors’ reservation levels remains unsupported. Type of 
pharmaceutical and centralization level proved to be significant and consistent as predictors of 
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1.1 Background  
Generic substitution at the Norwegian pharmacies was introduced in March 2001. The 
principle of the new regulation was to ensure a decrease in prices after the expiry of patents 
on original medicines, in order to contain the public pharmaceutical expenditures as well as 
those of the patients. After a decade in use, the scheme, together with the stepped-price 
system have been estimated to save the society about 2 billion Norwegian Kroner annually. 
Despite the undisputable success, generic substitution still faces some challenges, such as 
problems with correct use of the interchangeable medicines and some skepticism among 
patients (and some doctors). 
The scheme obliges the pharmacies to offer patients alternative and less expensive 
preparations (at stepped-price level), which are copies of the original drugs, but can differ in 
name, taste, and external features from those prescribed by doctors. Despite these differences 
both original and generic preparations contain the same active substance, and pass the same 
requirements for quality, effectiveness and safety. Still, patients must always be informed 
whenever the substitution takes place. 
In the presence of important medical reasons for which the patient has to be given the brand-
name product, such as high risk of non-compliance or adverse reaction to particular inactive 
substance, the doctors can make a note on the prescription here called a reservation note (an 
objection against substitution), to ensure that the pharmacy will dispose the original 
preparation instead of any alternatives. For reimbursable drugs with the doctor’s reservation 
on the prescription, the patient’s out-of-pocket payment remains the same as if the 
substitution did take place. The positive price difference between the original and generic 
medicines is in this case covered by the National Insurance Scheme. It is important to 
emphasize that doctors cannot issue reservation notes based on prejudices, skepticism or 




In situations when it is the patient who objects the substitution (patient’s reservation), without 
the note from his/her doctor, it is the patient who has to pay the price difference him/herself. 
The level of doctors’ reservations varies a lot across different areas of use and single 
substances. The average reservation rate across all substances is at the level of 5%, but for 
some preparations it can reach as high as 40% (for example, as in the case of an acid-
modifying medicine, omeprazole). There are surely clinical reasons for doctors to write 
reservation notes, but are these medical motivations exclusive factors in every case?  
 
 1.2 Main objectives 
The present study is an attempt on determining some of these non-medical reasons for 
variation in doctors’ reservation levels. Statistical analyses of a dataset reporting sales, 
reservation, prices and other variables (discussed in details in Chapter 5) are used to test 
potential factors (predictors) and their influence on the doctors’ reservation levels. In 
particular, the relationships between variables such as price difference between the original 
and generic alternatives, pharmacy chains, level of centrality (geographical location of 
dispensing pharmacy), type of pharmaceutical and the corresponding level of doctors’ 
reservations are being tested.  
 
 1.3 The thesis’ structure 
In the first part of the thesis (Chapter 2) a thorough description of the pharmaceutical system 
in Norway, along with pricing, reimbursement and generic substitution regulations will be 
given. Chapter 3 provides basic information on the pharmaceuticals selected for the analyses 
as well as on their users. The following part (Chapter 4) introduces some theory on 
prescription decisions in general and generic substitution in particular and some previous 





Chapter 5 presents the empirical part of the thesis: the methods used datasets, variables and 
statistical tools, while Chapter 6 contains reports on the results. The seventh and final Chapter 






































2. DESCRIPTION OF THE SYSTEM 
 
2.1 Norwegian Pharmaceutical system 
 
2.1.1 The Norwegian Medicines Agency 
The Norwegian Medicines Agency (NoMA) is the national, regulatory authority for 
medicines and the pharmaceutical supply chain. The agency is subordinate to the Ministry of 
Health and Care Services, and responsible for supervising the production, trials and marketing 
of medicines as well as their classification, pricing and reimbursement. NoMA approves 
medicines and monitors their use, and ensures cost-efficient, effective and well-documented 
use of medicines.  
 
2.1.2 Supply chain 
All major international pharmaceutical companies are active on the Norwegian market. Their 
market share is varied and rather dispersed, without clear dominants. The biggest company 
(Pfizer AS) controls 11.2 % of the market 
i
, there are also ten pharmaceutical companies 
producing medicines in Norway. Nevertheless Norway imports most pharmaceuticals. The 
majority of the companies are represented by the Association of the Pharmaceutical Industry 
in Norway (LMI-Legemiddelindustriforeningen).  
The distribution chain is constituted by (NoMA, 2008):  private pharmacies (581), publicly- 
owned hospital pharmacies (33), small pharmacy outlets [1200-sell selected over – the –
counter drugs (OTCs) and some prescription-only drugs (PODs) ordered from community 
pharmacies] and other retailers, which are only allowed to sell some OTCs (kiosks, 




The biggest retail channel (private pharmacies) is dominated by three pharmacy chains, which 
are vertically integrated with their own full-range wholesalers and control 98% of the market
i
. 
The three pharmacy chains together with their market shares are presented in the table below.  
Table 1. Distribution structure on the Norwegian Pharmaceutical market 
Pharmacy chain Owner Wholesaler Market 
share 
Vitus / Ditt 
apotek 















Source: Based on data from Apotekforeningen
 ii
 and  LMI 
i 
 
In addition, NMD supplies also hospital pharmacies. 
The pharmacies also have their trade organization – the Norwegian Pharmacy Association 
(Apotekforeningen). 
 
2.2 Pricing of pharmaceuticals in Norway 
The market for pharmaceuticals is generally characterized by low price elasticity of demand 
(broadly speaking, people want the medication they need but not more), and consequently 
high market power on the supply side. This creates a substantial producer surplus and a very 
unfavorable situation for the consumers. Norwegian authorities have introduced an extensive 
price regulation system to counteract high prices driving the health expenditures up, as well as 





The Norwegian Medicines Agency (NoMA) is in charge of pricing individual 
pharmaceuticals by establishing a maximum pharmacy purchasing price (PPP). This 
regulation refers to all prescription-only medicines (POM) which are to be launched at the 
Norwegian market. Prices of over-the-counter (OTC) medicines are subject of the free market 
price competition. The PPP set by NoMA is generally based on reference prices in nine 
Western European countries, which include: Sweden, Denmark, Finland, UK, France, 
Germany, the Netherlands, Austria, and Belgium. PPP is the average of the three lowest 
prices. The international price referencing system has been in use since July 2002 
(NoMA/PPRI, 2008). The selection of the reference countries is thought to be the most 
comparable to Norway. 
 
2.2.1 Pharmacy margin 
Pharmacy maximal margin rates are regulated only in case of prescription drugs and are 
currently at following levels 
iii
: 7% of the first 200 NOK of (Pharmacy Purchasing Price) PPP-
AIP and 4% of the remaining amount. In addition, there is a nominal margin of 22 NOK per 
package. A/B preparations (medicines containing narcotic or/and psychotropic substances) are 
subjects to the further 10 NOK of nominal margin per package. Table 2 presents the 
principles of margin regulation. 
 
PPP in NOK % Margin Nominal margin per 
package 
Addition per A/B 
preparation sold 
0 – 200 7  
22 NOK 
 
10 NOK >  200 4 
Table 2.  Maximal pharmacy margin calculation for prescription drugs in Norway 
 
The system allows for transparency and predictability of part of pharmacies’ income related to 
sales of the prescription drugs. For example the maximal margin for a medicine with PPP = 




Max Pharmacy Margin = (200 x 0,07) + (200 x 0,04) + 22 = 44 NOK 
In reality due to the strong vertical integration of the Norwegian pharmacy chains, the 
pharmacies are virtually their own wholesalers. And since the maximum margin regards only 
the pharmacy margins, the effective margin can be often even greater (Aarseth, 2001). 
According to the study by Brekke et al. (2010b), the average effective margin for prescription 
pharmaceuticals in Norway is approximately 18%. The margins in the study were calculated 
in the following way: 
M = (PRP-PPP) / PRP, where 
M = Pharmacy percentage margin, PRP = average Pharmacy Retail Price, PPP = average 
Pharmacy Purchase Price 
Section 2.4.4 contains further discussion on pharmacy margins and their implications for 
pharmacies’ incentives to promote generic substitution. 
2.3 Reimbursement regulation 
2.3.1 General reimbursement regulations 
The Norwegian health care system has been developed in consistency with the general 
welfare policy present in Norway since the end of World War II. The principal of equality of 
access to health and social services regardless of economic situation or geographical location 
has been the fundamental concept of this development. Health care as well as other state-
provided services are financed through compulsory and universal tax-based National 
Insurance System (NIS). There exists also a system of patients’ co-payments for out-patient 
care and reimbursed pharmaceuticals (the co-payment is 38 per cent). However the co-
payments are applicable up to the determined upper-ceiling, which in 2011 has been set at 
1 880 NOK
iv 
. After reaching this amount in co-payments, patients are relieved from 
payments for the rest of the calendar year and their medical expenses are fully covered by the 
NIS. According to OECD Health Data for 2008 
v
, total expenditure on health was 8.5% of the 
Norwegian GDP (out of which 7.6% was attributed to pharmaceutical expenditure). Public 





The NIS grants patients suffering from chronic and severe conditions the right to 
reimbursement of drug expenses. The treatment has to last for at least three months during a 
year to qualify for the scheme. The treatment must also fulfill criteria for cost-effectiveness. 
The NoMA publishes monthly the full list of pharmaceuticals which are eligible for 
reimbursement.  
2.3.2 Preferred pharmaceutical model 
“Preferred medicine” (called also a “first-choice’” or a “drug of choice” scheme) is a 
programme for reimbursable pharmaceuticals indicating products which are the most cost-
effective within a group of medicines for certain conditions. The regulation is applied for 
drugs with equivalent therapeutic effect when there are significant price-differences. The 
system has been introduced by the NoMA to ensure promotion of use of the most cost-
effective medicines and thus improvement of cost containment. The prescriber is obliged to 
prescribe the first-choice alternative. However in presence of serious medical reasons against 
the “preferred medicine”, the scheme ensures that the patient can have the individually best 
treatment reimbursed. One of the first groups of medicines covered by the scheme was lipid-
modifying agents, or cholesterol-lowering drugs (statins). Since June 2005, the prescribers are 
obliged to prescribe generic simvastatin to all new statin users, as well as switch their “old 
patients” using other statins to using simvastatin within transitional period of one year. 
Prescribing of other statins would continue for patients who cannot replace them with 
simvastatin for serious medical considerations. This reform proved to be very successful for 
the public budget, even though the number of statins users increases rapidly in Norway. 
According to the study by Sakshaug et al.(2007), who analyzed statin prescription in 13- 
month period before and following the introduction of the scheme, the proportion of new 
statin users prescribed simvastatin went up from 48% to 92%, resulting in decreased 
expenditure despite increase in prevalence of statin use. The study also found that nearly 40% 
of users of the more costly alternative atorvastatin, switched to simvastatin within one year 






2.4 Generic substitution 
2.4.1 Generic medicines 
According to the European Medicines Agency (EMEA/CHMP: 2011) a generic medicine is 
defined as a product that represents:  
 the same qualitative and quantitative composition in active substance(s) as the 
reference product,  
 the same pharmaceutical form as the reference medicinal product,  
 and whose bioequivalence with the reference medicinal product has been 
demonstrated by appropriate bioavailability studies.  
 
Generic medicines are generally copies of the original drugs that are no longer protected by 
patents. They contain the same active ingredient, though their composition may not be 
identical with the original. The incorporation of inactive ingredients which are different from 
the original formulation can make generics very different in appearance, with different colors, 
sizes and shapes from those of the originals. Still, the generic products must meet the same 
quality and safety standards as their branded counterparts. However, unlike the new original 
drugs, their generic followers are not required to go through complex, time- and resource-
consuming clinical trials of efficacy and safety, but they need to positively pass the 
bioequivalence trials. The manufacturers of the brand name preparation naturally use their 
privileged position of an exclusive seller in the patent period setting the prices high, trying to 
recover high costs and risks associated with research and development of new 
pharmaceuticals, as well as simply maximize their profit. In the post-patent period they often 
maintain the high prices (at least for some time), exploiting the drug’s strong identity and 
habits among prescribers and users (more on this in Chapter 4). It comes as no surprise that 
the generics are usually much less expensive than their original counterparts, as that is their 
chance to compete with the well-established original products. 
“Bioavailability” is defined as the amount of the active agent that finally reaches the site of 





Another central concept is bioequivalence. Two medicines are considered bioequivalent if 
they contain the same active substance and they have been tested to be of the same strength 
and finally they evoke the same effect in patients within the same time period. According to 
Birkett (2003), two products can be called bioequivalent if their bioavailability is similar 
enough to cause an effect of equal efficacy and safety. 
The EMEA (EMEA/CPMP: 2001) extends this definition stating that a generic medicine’s 
bioavailability has to lie between 80% and 125% of the original branded medicine. The 
EMEA emphasizes potential consequences of this interval. Patients, who are being often 
switched between different generic medicines, could receive a medicine with 125% 
bioavailability on one occasion, and 80% on the next. This would mean a 36% loss in 
bioavailability. If the patient were switched back to the 125% bioavailability medicine, they 
would experience a 45% increase in bioavailability. This change can impact on the control of 
the disease for the patient (EMEA/CPMP: 2001). Potential results of automatic generic 
substitution systems will be discussed further in chapter 4 of this thesis 
 
2.4.2 Substitution scheme 
All new pharmaceuticals entering the Norwegian market have to be registered, approved, and 
priced by the Norwegian Medicines Agency. The NoMA also creates a substitution list which 
includes interchangeable medicines. Pharmaceuticals must be approved as equivalent and 
interchangeable to be classified within the same substitution group. In practice, they are either 
generic versions of the original medicine or products coming from parallel import, i.e. 
virtually the same products as the branded ones already marketed in Norway, produced by the 
same manufacturer, but imported from a country where their price is lower. The substitution 
list is revised, updated and published by the NoMA on a monthly basis.  
In 2001 the New Pharmacy Act was introduced, giving the pharmacies the right to apply 
substitutions between equivalent drugs within the same substitution group (§6-6)
vi 
when 
dispensing prescription medicines. The scheme intends to increase price competition as well 
as reduce drug expenditures for both patients and the National Insurance System. 
Presently, the pharmacies dispensing medicines are obliged to inform patients about the 




substitution group. Thus regardless of the prescribed trade name of a specific drug, a patient 
will be advised about the cheapest option, usually the generic one, containing the same active 
substance of the same form and strength. Patients can reject the substitution. However, they 
will have to bear the positive price difference between the generic alternative and the original 
medicine themselves. Also in case of reimbursed drugs the patient will have to bear the price 
difference. This price difference will not count as part of the 1880 NOK which is the upper-
ceiling for co-payments in NIS. In the presence of important medical reasons to why a patient 
has to use the branded name medicine, the prescriber can reserve against generic substitution 
by making a note on the prescription. These important clinical reasons can include the 
patient’s allergy to some of the inactive ingredients of generics, observed side-effects as well 
as significant risk of inappropriate use by patients used to using brand-name medications and 
confused by different appearance of the generic drugs (lack of compliance). In case of 
reservation against generic substitution is made by the prescriber, the difference in price is 
covered by the NIS. Effectively, the patients’ out-of-pocket contribution remains unchanged. 
2.4.3 Stepped-price model  
When the patent protection period ends, and the original medicine is exposed to generic 
competition, the wholesalers’ power to negotiate lower prices with the manufacturers 
increases. Sometimes they are able to acquire decreased prices also for the branded name 
pharmaceuticals. The stepped-price model was introduced in Norway in January 2005 to 
ensure that both patients and the NIS also benefit from this surplus created on the demand 
side. The new system forces the prices down. Because of the lack of price-sensitivity on the 
demand side, a price reduction to this extent would not take place without regulation. Without 
a system for price reduction, the distribution chain would benefit from lower purchasing 
prices due to generic competition. The retail prices however, would not be reduced to the 
same degree.  
In the stepped price model prices are being gradually reduced by predefined rates. The system 
has been modified twice since its introduction; the last modification was implemented in 
January 2008. The degree of price reduction is dependent on annual sales turnover of a 
particular medicine. Stepped price is the maximum price reimbursed by the NIS expressed as 
a fraction of the maximum retail price (PRP) of the original preparation at the end of the 




reimbursable drugs the stepped price is also sometimes referred to as the reimbursed price. 
The principles of the model are presented in the Table 3 
Table 3 The stepped price model. Source: NoMA. Percentage figures represent price reductions in relation to the original 
maximum PRP 
 
Sales PRP, 12 months before generic 
competition 
 
≤ 100 million NOK 
 




Time of price-cut 
Start of generic competition 








Sales PRP,  ≥ 12 months after 2nd step 
 
>15 million NOK and ≤ 
30 million NOK 
>30 million NOK 
And < 100 million 
NOK 




Time of price-cut 







PRP=Pharmaceutical Retail Price 
 
 












Table 4. Example of price calculation for a pharmaceutical with initial price of 1000 NOK 
and with annual sales for over 100 mln NOK, exposed to generic competition and subject to 























































































*Patient’s co- payment is presently 38% of the PRP. Not applicable once the ceiling of total annual contribution 1880 NOK 
is reached. **Given that the price of brand name product remains unchanged 
 
The pharmacies are obliged to have at least one preparation within each substitution group 
available at the stepped price. The stepped price does not depend on the purchasing prices of 
the wholesaler or the pharmacy. The construction of the scheme therefore encourages them to 
lower their purchasing prices. Since the reimbursed price is virtually fixed after one year, the 
whole supply chain’s actors from the manufacturers to the pharmacies have strong incentives 







2.4.4 Why generic substitution? 
Since 2005, the generic market share in Norway has been relatively stable and accounted for 
approximately 46% of the volume expressed in DDD (defined daily doses) and about 64% of 
the sales measured in PPP (Pharmacy Purchasing Price). 
i
 
Norwegian public authorities actively promote generic substitution for cost-containment 
reasons. According to the NoMA
vii 
about 2 billion NOK are saved every year due to the 
generic substitution and the stepped-price system. Approximately 75% of this sum benefits 
the National Insurance budget while 25% benefits the patients.  
The pharmacies also play a crucial role in the generic substitution scheme. Generally, due to 
the transparency and simplicity of the stepped price system, the economical outcomes are 
relatively predictable for all supply chain parties. The time and effort that the dispensing 
pharmacies spend on convincing patients to generic alternatives can influence generic sales 
and thus total pharmaceutical expenditures. Therefore they must be economically motivated 
to dispense generic drugs. The strong vertical integration existing between Norwegian 
pharmacies and wholesalers increase their power in negotiating lower prices with the 
manufactures. The pharmacies and wholesalers are allowed to keep the surplus between the 
stepped-price and their real purchase price. This translates directly into higher margins for the 
pharmacies giving them financial incentives for promotion of the generic substitution. 
Brekke and his colleagues in their empirical study (Brekke et al. 2010a), analyzed the impact 
of pharmacy margins on the pharmacies’ incentives for promotion of generic products in 
Norwegian settings. They compared ex-manufacturer prices with retail prices and observed 
that the pharmacies have substantially higher margins on generics than original drugs 
measured either as percentage margins or absolute margins. They also found a strong 
association between brand-name and generic margins and their market shares. The 
pharmacies are inclined to expend more effort in promoting generics when their margins are 
high relative to the brand-name products. This incentive is also increasing the lower the 
generic co-payment becomes relative to the brand name co-payment. In addition, the 
researchers concluded that a regressive mark-up scheme, that provides lower absolute margins 
on higher priced drugs (original drugs), will provide pharmacies with incentives to spend 




Last but not least, generic substitution gives individual medicine users the possibility of 



























3. INFORMATION ON THE SELECTED 
PHARMACEUTICALS AND THEIR USERS 
 
Nine different substances among three ATC (Anatomical Therapeutic Chemical) groups have 
been selected for this analysis.  
Table 5. Substances selected for the analysis 
ATC  code Active agent Class Main indication 
A02BC01  omeprazole  Proton pump inhibitors  Peptic ulcer/GERD 
A02BC02 pantoprazole  Proton pump inhibitors  Peptic ulcer/GERD 
A02BC03 lansoprazole Proton pump inhibitors  Peptic ulcer/GERD 
A02BA02 ranitidine H2-receptor antagonists  Peptic ulcer/GERD 
C10AA01 simvastatin HMG CoA reductase  High cholesterol level 
C10AA03 pravastatin HMG CoA reductase  High cholesterol level 
N06AB04 citalopram selective serotonin reuptake inhibitors  Major depression 
N06AB05 paroxetine selective serotonin reuptake inhibitors  Major depression 
N06AB10 escitalopram selective serotonin reuptake inhibitors  Major depression 
 
The sections below present general descriptions of the selected pharmaceutical together with 
their prevalence of use in Norway in the past few years and some demographic features of 
their users. 
 
 3.1 Statins 
Cholesterol is a vital component of the cell membranes as well as bile acids, steroid 
hormones, and fat-soluble vitamins including Vitamin A, Vitamin D, Vitamin E, and Vitamin 
K. It is critical to the normal function of every cell in the body.  However, the elevated level 
of cholesterol in the blood serum contributes to the development of atherosclerosis causing 
chest pain and becoming a major risk factor for cardio-vascular diseases (CVD), including 
heart attacks and stroke. 
Statins are a class of drugs used for preventing and treating atherosclerosis that lower the level 




the enzyme in the liver that is responsible for making cholesterol. This enzyme is called 
hydroxy-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). Scientifically, statins 
are referred to as HMG-CoA reductase inhibitors. By reducing the production of cholesterol, 
statins are able to slow the accumulation of lipids in artery walls (plaques) and occasionally 
can reduce the size of plaques that already exist. In addition, through mechanisms that are not 
well understood, statins may also stabilize plaques and make them less prone to rupturing and 
promoting the development of clots (Medicine net 
xii
). The crucial role of cholesterol in 
atherosclerosis is widely accepted by scientists. In addition to lowering cholesterol levels, 
statins also reduce inflammation, which could be another mechanism by which statins 
beneficially affect atherosclerosis. This reduction of inflammation does not depend on statins' 
ability to reduce cholesterol. Furthermore, these anti-inflammatory effects can be seen as 
early as two weeks after starting statins. The statins’ indication area is therefore broadening. 
Still, most patients are placed on statins because of high levels of cholesterol. Though 
reduction of cholesterol is important, heart disease is complex and not always high cholesterol 
alone contributes to its development. Thirty-five percent of individuals who develop heart 
attacks do not have high blood cholesterol levels, yet most of them have atherosclerosis.  
Statin use is in general safe and well tolerated in all categories of patients, including the 
elderly at risk. Serious side effects such as rhabdomyolysis (muscule fiber break down and 
enter the bloodstream) or severe liver damage are very rare but have been reported. Mild side 
effects may be managed by reducing statin dose or switching to another type of statin. 
However, sometimes discontinuation of the statin may be necessary.  
Concluding, because of their efficiency, few contraindications and general safety, statins are 
expected to be increasingly used in the prevention and treatment of cardiovascular disease. 
Given the very high social and economic burden of cardiovascular diseases in most countries, 
it is not surprising why statins are attracting lots of attention from practitioners, patients, as 
well as policy makers.  
Also in Norway the use of statins has been growing steadily in the recent years, becoming the 
second group of pharmaceuticals (measured in DDDs), among the most used 
i 
. In fact, 
measured in DDDs, the sale of statins in Norway is higher than in most other European 
countries.
xiii




since the prescribed daily dose has increased over time. As described in the study by 
Sakshaug et al.(2007), the introduction of new price and reimbursement regulations for the 
statins have resulted in reduced cost in the latest 5 year period, despite the increase measured 
in DDDs.  When simvastatin was made the drug of choice in June 2005, many users had to be 
switched from more costly alternatives to simvastatin.  
For the present analysis we have chosen two popular substances among statins: simvastatin 
(statin with most users and 5
th
 most used medicine in Norway) and pravastatin. Table 6 and 
chart 1 presented below show the specification and number of users of the two substances and 
its development over the past few years.  
Table  6. Statins – number of users per substance and year. 
ATC  level 
Active 
agent Class 
Name of the 




    
        2006 2007 2008 2009 
C10AA01 simvastatin 
HMG CoA 
reductase Zocor 254955 321025 348044 356617 
C10AA03 pravastatin 
HMG CoA 
reductase Pravachol 28113 24230 23056 22324 
TOTAL 
  
  283068 345255 371100 378941 
Source: Based on numeric data from Legemiddelstatistikk 2010:2 The NoPD 2005-2009 
 
One of the many common risk factors for arthrosclerosis and CVDs is age. Men over 45 years 
and women over 55 years of age are considered to be in a higher risk of developing serious 
CVDs. This is also reflected in the age interval for patients on statin therapy. The absolute 
majority of statin users are 45 years and over. See Chart 1 for age distribution for users of 








Chart 1. Users of the selected  statins in Norway by age. Data from 2009 
 
Source: Based on numeric data from Legemiddelstatistikk 2010:2 The NoPD 2005-2009 
 
3.2 Acid-suppressing drugs 
Acid-suppressing medications (ATC: A02B) used mainly in therapies for peptic ulcer and 
gastroesophageal reflux disease (GERD) chosen for this study belong to two sub-groups: 
Proton pump inhibitors (PPI) and histamine H2 antagonists (blockers). List of the selected 
acid-suppressants is presented in the table 7. 
Both PPIs and H2 blockers suppress gastric acid secretion, but at different stages of 
production. While histamine blockers block one of the first stimuli for acid production, proton 
pump inhibitors block the final step in the pathway of acid secretion in the stomach, resulting 
in greater suppression of acid. PPIs block the enzyme in the wall of the stomach that produces 
acid, H2 blockers work by blocking the histamine receptors in acid producing cells in the 
stomach. PPIs have a delayed onset of action, while H2 Blockers begin working within an 
hour. PPIs work for a longer period of time; most up to 24 hours and the effects may last up to 
three days. H2 Blockers, however, usually only work up to 12 hours
xii
. Despite these 
differences both groups of drugs reduce level of acid preventing formation of ulcers, and 
allow any ulcers that exist in the esophagus, stomach, and duodenum to heal.  Apart from 




Zollinger-Ellison syndrome and elimination of helicobacter pylori (in combination with 
antibiotics). 
Table 7. Acid suppressing medications - number of users per substance and year. 
ATC  
level Active agent Class 
Name of the 
original product  Number of users in Norway   
        2006 2007 2008 2009 
A02BC01  omeprazole PPI Losec 27013 40043 44878 46831 
A02BC02 pantoprazole PPI Somac 12691 57061 74962 85127 
A02BC03 lansoprazole PPI Prevacid* 37108 48558 50409 49988 
A02BA02 ranitidine 
H2-receptor 
antagonists Zantac 44649 50383 55440 55433 
TOTAL 
   
121461 196045 225689 237379 
Source: Based on numeric data from Legemiddelstatistikk 2010:2 The NoPD 2005-2009* Original unavailable 
on the market 
Proton pump inhibitors are very similar in action and there is no evidence that one is more 
effective than another. They differ in how they are broken-down by the liver and their drug 
interactions. The effects of some PPIs may last longer and they, therefore, may be taken less 
frequently. For the present analysis we have chosen three popular PPI: omeprazole, 
pantoprazole and lansoprazole as well as the very popular H2 blocker: ranitidine. Ranitidine, 
omeprazole, and pantoprazole are also sold as OTC drugs in Norway. The proton pump 
inhibitors (ATC group A02BC) had a growth of 9% measured in doses sold in 2009; 
approximately the same increase as the years before. Since 1
st
 February 2007 lansoprazole, 




Risk factors for developing gastric acid-related diseases are: Infection with Helicobacter 
pylori, stress, diet, use of anti-inflammatory drugs, alcohol and tobacco use, as well as age 
over 45. The peak for gastric ulcer development is between ages 55 and 65. Nevertheless, the 
people younger than 45 make up a quarter of patients receiving acid-suppressing medications 






Chart  2. Users of the selected proton-pump inhibitors in Norway by age. Data from 2009 
 
Source: Based on numeric data from Legemiddelstatistikk 2010:2 The NoPD 2005-2009 
 
 
 3.3 Anti-depressants 
 
Antidepressants are psychiatric medications used to alleviate mood disorders, such as major 
depression and dysthymia and anxiety disorders such as social anxiety disorder (Medicine net 
xii
). Antidepressants are the most prescribed therapy for depression. The exact mechanism of 
action of antidepressants is unknown. The prevailing theory is that antidepressants increase 
the concentration of one or more brain chemicals (neurotransmitters) that nerve cells in the 
brain use to communicate with one another. The neurotransmitters affected by antidepressants 
are norepinephrine, serotonin, and dopamine. The different classes of antidepressants differ in 
the neurotransmitters they affect. This determines some of their side effects and potential drug 
interactions. All available antidepressants are effective, and for most cases of depression there 
is no good evidence that any antidepressant is more effective than another. Side effects and 
potential drug interactions are major factors that influence selection of antidepressants and 
compliance with therapy. The major antidepressant classes include: monoamine oxidase 
inhibitors (MAOIs), tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), 




inhibitors (SNRIs). These medications are among the most commonly prescribed by 
psychiatrists and other physicians in Norway (Medicine net 
xii
). Data from the NorPD show 
that 292 000 individuals had at least one antidepressant prescription dispensed in 2009, 
women accounted for 65%. During the last three-year period the number of patients using 
antidepressants has remained unchanged
xiii
.  
The present study includes three selected preparations among the selective serotonin reuptake 
inhibitors (SSRIs) group. See the table below. 
 
Table 8. Selected antidepressants - number of users per substance and year. 
ATC  level Active agent Class 
Name of 
the original 
product  Number of individuals     
        2006 2007 2008 2009 
N06AB04 citalopram SSRI Cipramil 41271 38151 35569 32859 
N06AB05 paroxetine SSRI Seroxat 21310 19829 18698 17503 
N06AB10 escitalopram SSRI Cipralex 76436 87539 93702 98454 
TOTAL       
139017 145519 147969 148816 
Source: Based on numeric data from Legemiddelstatistikk 2010:2 The NoPD 2005-2009 
 
The general indications for SSRIs use is quite broad and include: major depression, obsessive-
compulsive disorder, panic disorder, post-traumatic stress disorder, but also social anxiety, 
premenstrual dysphoric disorder (PMDD), and panic attacks. 
Escitalopram is noted for its high selectivity of serotonin reuptake and it is the most 
commonly prescribed antidepressant in Norway. Its efficacy and acceptability in the acute-
phase treatment of adults with major depression is well established. Escitalopram is the S-
stereoisomer (enantiomer) of the earlier Lundbeck drug citalopram, hence the name 
escitalopram. Despite the similarity of escitalopram and citalopram, various clinical studies 
have shown differentiated effects of citalopram and escitalopram, especially in severely 
depressed patients (Medicine net 
xii
). The sales of escitalopram (Cipralex) increased by 9 % in 




had a share of 47% of the ATC group N06A measured in NOK. Escitalopram is included in 
the list of top 10 ranked prescription drugs according to sales.
xiii
 The index group pricing 
system, and later the stepped price model has led to an extensive price reduction on 
antidepressants not covered by patent protection and where cheaper generic alternatives are 
available. Until 01/03/2010 escitalopram was only available in Norway in its original version 
– Cipralex.  
Although the precise cause of mood disorders is not known, certain factors seem to increase 
the risk of developing or triggering depression, including, among others: family history, 
traumatic experiences in childhood, stressful life events, substance dependence, presence of 
serious illness, certain personality traits. Mood disorders can become apparent at any age, 
with depression beginning typically in the late 20s. Twice as many women are diagnosed with 
depression as men, but this may be due in part because women are more likely to seek 
treatment for depression (Medicine net xii). See the charts below for gender and age 
distribution for antidepressant users in Norway. 
Chart 3. Users of the selected antidepressants  in Norway by gender. Data from 2009 
 









Chart  4. Users of the selected antidepressants  in Norway by age. Data from 2009 
 







































4. PRESCRIPTION DECISIONS – THEORETICAL 
FRAME 
 
 4.1 Patient – doctor – health care system relationships 
 
The primary ground of each doctor’s professional ethos is to protect his or her patients’ life 
and health. This role is to be carried out in the best possible manner within a given system of 
resources and organization. In modern times, regardless of the form for financing of health 
care systems, doctors face problems of scarcity of recourses and growing costs. Progress in 
health technology, prolonged life expectancy combined with ageing populations in most of 
the developed countries, put health care systems under increasing pressure.   
The vast majority of doctors (96%) surveyed by Arnesen and Fredriksen in a Norwegian 
study (1995) admit that the gap between what would be ideally required for their patients, and 
what can be offered within the national health care system, is widening and that prioritizing 
decisions are necessary. 
The ethical guidelines of the Norwegian Medical Association emphasize the doctors’ double 
responsibility towards patients, as well as the society in general. A doctor should safeguard 




Cooperation in decision-making based on 
informed consent is crucial. Patients have the right to information on their health condition 
and therapies. At the same time, doctors are also obliged to take responsibility for common 
resource distribution 
viii
. Lundin (2000) calls it a double-agency role and indicates the 
potential for moral hazard.  
The moral hazard is the consequence of asymmetry in information between doctors as 
government’s agents representing interests of both the national health care system and the 
patients, and their principal – the NIS (the party that commissions and pays for the agent’s 
actions). The physicians have more information about their patient cases and about their own 




monitor all doctors’ action at all times. The doctors may have incentives or tendencies to 
behave differently (for example set their patient’s interest above the budget constrains) than it 
would be expected of them. This is more likely to happen when the societal interest and 
individual interests are contradictory.  
The dual nature of doctors’ obligations was the subject of Arnesen’s and Fredriksen’s study 
(1995). As the result 95% of the questioned GPs experienced a conflict between their 
responsibility towards patients and equitable allocation of health care resources. Interestingly, 
most doctors also admitted that individual patients should be given priority, since the society 
is rather perceived as an anonymous, undefined mass. 
At the same time, as indicated in the study by Sakshaug et al. (2007), the physicians feel 
responsible for their cost-containment role when making prescription decisions. 
It seems that in order to reconcile their double-agency role, the doctors have to try to find 
optimal balance between the two commissions. The modern medicine ethical framework 
could be such as proposed by Hope et al. (1998), listing effectiveness, equity and patient 
choice as its key areas. 
Although individual physicians can assign different weights to those three values while 
making their treatment decisions, the organization of health care system, with its regulations, 
tools and incentives, plays a fundamental role in these processes. 
An introduction of the patient-list system in the Norwegian general practice in June 2001 can 
serve as a good example. The reform brought mayor changes to the rules of physicians’ 
payment and introduced free choice of GPs. Before the reform, 40% of GPs’ income came 
from the so-called “practice allowance” from the municipality and the remaining part came 
from the activity-based component (consultation fee and patients’ out-of-pocket payment). 
After June 2001 the practice allowance was replaced with the capitation fee, which presently 
makes 30% of the GPs’ income, the remaining 70% is an activity-based income. Introduction 
of the capitation component means that the number of patients on the individual doctor’s list 
strongly influences their income. Patients have the right to choose their GP and change their 
mind up to twice a year. The GPs receive monthly reports on the number of their patients as 
well as which patients have joined or left their list 
ix
. The reform implies a closer link between 




the same time, general practitioners have to remain gatekeepers for the rest of the health care 
system. Gate-keeping role includes referrals to specialist care, issuing sickness certificates and 
prescribing reimbursable drugs.  
Carlsen and Norheim (2003) have investigated the shift in power between physician and 
patient towards the patient after introduction of the patient-list system. The authors discovered 
that doctor’s perception of their gate-keeping role has weakened. Instead, the GPs want to 
keep their patients satisfied and provide excellent individual service. The physicians feel that 
their new environment is characterized by increasing competition, higher expectations or even 
demands from patients and more responsibility on their part. It has become more important to 
meet these expectations. GPs have become more concerned about their list’s length, thus its 
influence on their income and reputation and less concerned with reducing unnecessary 
resource use. 
What about the interest of the society then? Do the arguments of social interest that doctors 
have to follow, interfere with doctor-patient relationship? Willems (2001) reminds that the 
discussed gate-keeping role is controversial due to the organic conflict between patient and 
societal interest. The duty should first of all apply to patients and not to entire populations. 
However, Willems argues that it is possible to integrate societal arguments into practice in 
morally acceptable way (2001). It is about balancing the fair distribution of health care with 
appropriate (effective) care for individuals within budget constraints. It is about balancing 
values and rationalities (Willems, 2001). 
The doctor – patient relationship can be described by different models and is often of a 
dynamic nature. Emanuel and Emanuel (1992) are describing four different models of that 
relationship: paternalistic, informative, interpretive and deliberative. The comparison of these 
four forms is presented in the Table 5. 
According to Emanuel and Emanuel (1992) a doctor-patient relationship evolved from the 
paternalistic one, with doctor as a guardian of the patients health and life, towards models 
based on mutual communication, where a doctors maintains the role of a counselor, technical 
expert but also becomes a friend and teacher. The authors are trying to defend models based 
on patient’s empowerment but allowing the doctor an active role in informing, counseling and 




Table 9 Four Models of the Physician-Patient Relationship. Source: Emanuel EJ and Emanuel 
LL.  "Four Models of the Physician-Patient Relationship." JAMA 1992, 267(16):2221-6 
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 4.2 Factors affecting prescription decisions 
 
In the era of growing use of pharmaceuticals and their costs, rational prescribing becomes 
increasingly important. The prescribing decisions should be most of all dictated by medical 
considerations, appropriateness of use and expected therapeutic effect. However, in the 
presence of wide range of alternative products available on the market, there are numerous 
other factors that contribute to the final choice of the medicine. 
4.2.1 Prices 
In the world of perfect competition, the price of a product is the only variable that makes a 




In reality, it is difficult to find an example of such a market. The pharmaceutical markets 
seem to be particularly far from the ideal. These markets are characterized by very low price 
elasticity, thus the consumers’ reactions cannot be expected to follow patterns of other 
markets. What about consumers’ willingness to substitute or their indifference rate between 
two alternative medicines: original and generic? Bioequivalent preparations, though described 
as substitutes are often far from being perceived as such by both prescribers and their patients. 
To what extend then is the price a deciding factor in the choice between original and generic 
medications? 
The physicians seem to be aware of the impact of their decisions on health care budgets. In a 
Canadian study by Polinski et al. (2008) as many as 87% of GPs, acknowledge an economic 
appropriateness of generic substitution. When it comes to clinical appropriateness, only 70% 
expressed their positive attitude. However, as much as 43% of GPs had limited knowledge of 
real drug costs (Polinski et al. 2008). So are the doctors’ prescribing habits sensitive to prices? 
If so, are the prices paid by the patients or those paid by the insurer (or NHS) which count? 
Furu et al. argue in their study on generic substitution (2008) that doctors lack direct 
economic incentives to let prices affect their prescription choices. The physicians can be 
however sensitive to their patient’s preferences based on prices. This extensive Norwegian 
study found evidence that patients are more likely to be dispensed generics if the price 
difference between brand name and generic increases (results of the study summarized also in 
the paper by Dalen et al. 2011). 
This observation was also made earlier in a Swedish study conducted by Lundin (2000), 
analyzing prescribing patterns for brand name vs. generic drugs. The study examines impact 
of several factors: price as well as patients’ and doctors’ acquired tastes. Lundin (2000) argues 
also that the answer to the question: who is paying? is fundamental when choosing between 
alternative versions of a medication. Patients having to pay large sums for original drug are 
more likely to have generic prescribed. Lundin (2000) indicates that about 60% of the change 
in market shares between alternative versions can be explained by differences in prices not 
qualifying for reimbursement. If the price difference covered by the patient increases; the 




Similarly, the Norwegian study found that patients reimbursed by the NIS are more likely to 
use the brand name preparations (Dalen et al. 2011). 
These results suggest that when considering prices as contributing factors to prescribing 
decisions, it is important to remember that it is not the price levels per se, which are 
important. It is most of all, costs covered by patients, determined largely by the health 
insurance system functioning in the study settings. Type of reimbursement schemes can make 
patients (and not least the doctors) either very aware or ignorant about the real drug prices. 
The consequences of such ignorance can have a negative effect for the public health budget. 
As reminded by Lundin (2000) in insurance based systems over-consumption of medical care 
is more likely. In a situation where most of drug costs are covered by the common insurance 
and where there is a possibility of prescriber’s reservation against generic substitution, 
without impact on patients’ personal costs,  patients may develop an attitude of indifference 
towards nominal prices (and sensitivity to their own costs) of alternative preparations, keeping 
their preferences towards particular brands. This hypothesis, together with doctors’ sensitivity 
towards their patients’ expectations, are to some extend tested by the present study. 
4.2.2 Patient’s expectations  
As mentioned above, along with the progress in medicine as well as the increasing access to 
information, the relationship between doctors and their patients evolves towards increased 
partnership and more patient-centered care. The character of this relationship remains in close 
connection with the cultural, economical and systemic settings. Again, the type of health care 
system organization plays a crucial role. 
The 2001 primary care reform in Norway, which introduced patients’ list empowered patients, 
giving them a free choice of their primary care physician. According to Carlsen’s and 
Norheim’s study (2003), many physicians feel that they are now under higher pressure to 
meet their patients’ expectations in order to attract and keep them on their list. 
In another study (Gulbrandsen et al., 2002), more than a half of physicians admit that 
sometimes or often they gave more weight to patients' wishes than to their own medical 
judgment. As many as six out of seven doctors sometimes or often met unrealistic demands 
from patients, including adjusting sickness certificate in order to help them (>50%) 




Also, according to Britten (1994), most patients have clear expectations of their doctors’ 
prescribing habits and they simply expect prescriptions. Patients might favor doctors, whose 
prescribing habits they accept. Dissatisfaction with prescription patterns might be a reason for 
which patients leave the lists (Britten 1994). 
We find yet another confirmation of the patients’ influence, in the Cockburn’s and Pit’s study 
(1997), where the patients who expected medications on their doctor consultation were 3 
times more likely to be prescribed medication than the patients who did not have pre-visit 
prescribing expectations. However, doctors’ perception of the patients’ expectation has an 
even stronger impact on their own prescribing behavior. If the doctor was convinced that his 
patient expected prescription, this patient was ten times more likely to leave the practice with 
prescription than if he did in the situation when the doctor had not such assumptions 
(Cockburn and Pit, 1997). This suggests that doctors tend to overact to patients’ expectations 
as perceived by their doctor when it comes to prescribing.  
The doctors’ tendency to overestimate patients’ expectations is also mentioned in a British 
study by Hamilton et al. (2006). 
It seems that some doctors are extensively sensitive towards their patients’ expectations. Does 
it bring exclusively positive outcomes? Certainly not, since it can clearly lead to waste of 
resources. Paradoxically the doctor’s reputation may also suffer. Surprisingly, Britten’s study 
(1994) reveals that the interviewed patients were praising their doctors for not over-
prescribing, not being too submissive and not giving the patients whatever they demanded. 
 
4.2.3 Prescribing habits and brand loyalty 
The period of patent protection gives the pioneering company a favorable position of an 
exclusive seller. The monopolist rank allows the inventor to dictate higher prices and thus 
recover (to various extents) the development and research costs of the new formulation. 
Presently the patent period after complement of all required trials is usually no longer than ten 
years. This, however, often proves to be sufficient to develop a strong identity (brand name, 
information on indications, effectiveness) of the pharmaceutical product among prescribers 




original manufacturer to maintain prices on a higher level for some time, even after the 
cheaper competitors enter the market. 
The habits can linger for both the patients and the doctors. Initial lack of, or delayed 
information, and ignorance about price differences can be helping the prescribers in persisting 
in the old habits. 
For some patients it may be difficult to acknowledge that preparations with different external 
features can bring the same therapeutic effect (Furu et al. 2008; Dalen et al.2011). 
In addition, if both patients and doctors are insulated from the additional costs of a brand-
name drug compared with generic, there is no real motivation why any of the two would 
prefer the generic preparation over the original one (Lundin, 2000). 
Prescribing habits and brand loyalty strongly correlate with prescribers’ and patients’ 
characteristics. Coscelli (2000) differentiates patient-level and doctor-level factors 
accountable for differentiation of bioequivalent preparations. Among the patient - related 
factors are: gender, age, number of prescriptions, number of doctors, number of prescribed 
substances and past switches between alternative medications. At the prescriber – level, 
quantity prescribed and brand concentration index played primary roles. 
Hellerstein (1998), after studying micro-data from surveys on doctors concerning drug choice, 
discovered that the prescribers’ variables are dominant in determining whether a patient 
receives prescription for original or generic drug. In Hellerstein’s study, the patients’ 
characteristics turned out to explain very little of the variation in prescriber’s decision (1998). 
By contrast, Furu et al. (2008), after analyzing an extensive data file from The Norwegian 
Prescription Database (NoPD) (study summarized in paper by Dalen et al.2011), found 
evidence for an influence of both physician’s and patient’s characteristic on the medication 
choice. The impact of age of both parties is particularly pronounced. The older they are, the 
more likely they are to have preferences for the brand-name version. Apart from the nominal 
age of the patients or doctors, the question of how long the patient has been using a particular 
preparation is also deciding. Those, who are using the generic drugs, are almost entirely new 
patients, who use the drug type for the first time. In addition to the age factor, male doctors 




also estimated that general practitioners were more likely to have patients choosing brand-
name drugs when compared with patients of hospital doctors. 
 
4.2.4 Marketing 
Advertisement and other marketing tools used by manufacturers/sellers play usually a vivid 
role in consumers’ choices. Is this also the case when it comes to medications?  
Advertisement of pharmaceuticals is highly regulated in Norway. Relevant legal framework 
has been detailed by Forskrift om legemidler, §13 (Regulations for Pharmaceuticals)
x
. 
According to the law 
x
, advertising directed to the public is only allowed for approved OTC 
(over-the-counter) preparations and only in specified media. When it comes to POD 
(prescription-only-drugs) such advertisement can only be directed to health professionals 
(doctors, dentists and veterinary doctors) through direct channels (without the media). They 
can only contain basic information about the medicines and cannot be accompanied by any 
objects, gifts, services, premiums or anything that presents economical value. In addition, the 
named health personnel are banned from accepting such benefits. Free samples can be sent to 
the specified health professionals only at their own requisition and only in quantity of one 
sample of a specific medicine per year.
 x
 Despite these strict regulations, the pharmaceutical 
industry makes use of  other channels to stream down their marketing activities. According to 
the NoMA’s report (Madsen, 2003), doctors are the industry’s most important cooperates, and 
GPs make their key target group. The report estimates that the industry’s marketing 
expenditure in Norway reaches over 500 million NOK annually. The doctors’ need for 
continued education, guidelines on new treatments and new medicines, which is often 
fulfilled by training sessions, individual meetings with drug consultants, seminars, 
conferences (often involving foreign trips), are sponsored or heavily subsidized by the 
pharmaceutical industry. Incomes from adverts are also important source of financing for 
medical magazines. Many patients’ organizations rely on subsidies from pharmaceutical 
companies.  
All these activities certainly have their effect on prescribing and use of drugs. The NoMA as a 
state agency and regulatory body, appreciates the industry’s legitimate need for marketing of 




better reporting on marketing activities, and making such information publicly available 
(Madsen, 2003). 
 
4.2.5 Other factors 
Furu et al. (2008) found that in the Norwegian settings pharmacies play an active and 
important role in the ultimate choice between substitutable alternatives. In absence of the 
prescriber’s reservation against generic substitution, the actual decision on the drug version 
takes place in the dispensing pharmacy.  
Pharmacies are obliged to offer a preparation at the lowest price level – the stepped- price 
(NoMA, 2008), as well as to provide information of the pharmaceutical. Patients can either 
accept the version recommended by the pharmacy or insist on having the brand – name 
product. In this case, the patients cover the additional price difference.  
Furu et al. (2008) discovered that pharmacy identity is important in convincing patients to 
accept generic substitution. The authors suggest that time and effort that pharmacy personnel 
spend on persuasion are strongly influenced by economical incentives, strictly pharmacy 
margins, which are affected by procurement prices and varied among different pharmacy 
chains. This would explain why some pharmacy chains report higher levels of patient 
reservation against generic substitutions than others do.  
Another explanation might be that the original may be available at the stepped price in one or 
some of the pharmacy chains. This would lead to a lower patient reservation rate. 
Another factor listed by Furu et al. (2008) is the so called “market age” of generic 
competitors. In younger competition markets the brand - name loyalty plays in important role 








4.3 Discussion around generic substitution 
The generic substitution system can serve as a very efficient tool in forcing more competition 
in the pharmaceutical sector and helping with containing escalating costs in the other parts of 
the national health care. It can prove to be also satisfactory to other parties: pharmacy 
wholesalers, chains and generic producers, at least in economical terms. The possibility of 
using cheaper alternatives is valuable to most patients, who cover entirely or partially the cost 
of their drug therapies. 
Due to increasing drug expenditures, several Western European countries with both tax and 
insurance-based financing of the health care have introduced some sort of generic 
competition, either in form of generic prescribing or generic substitution at dispensing.  
There is however some controversy around the use of generics instead of the brand-name 
products. The recent debate on generics in the UK can serve as an example. Last year’s 
attempt of introduction of the automatic generic substitution (similar to the one functioning in 
Norway) by the Department of Health evoked so much protest from doctor and patient groups 
that the proposal had to be abandoned. Apart for the usual arguments of varying 
bioavailability and problems with adherence (which I describe more in detail below), the 
adversaries raised the issue of responsibility for health outcomes, in situation when the 
medication would be substituted at the pharmacy counter and the prescriber would not be 
aware of the substitution. Prescribing in the UK looks however a little different than in 
Norway. Traditionally, prescribers in the UK have been using the active substance name on 
the prescription. Generic prescribing has already reached a high 83% (Solanki, 2009) and the 
General Practitioners Committee estimated that an automatic generic substitution would result 
in about 0,4% of drug cost reduction. Such a comparatively small saving to the National 
Health Service (NHS) was probably the reason why the proposal was ultimately rejected. 







4.3.1 Problems with compliance 
Chemist and pharmacists understand that generics are in fact substitutable to the brand name, 
although the products often appear to be different. Patients however, are more interested in 
the medication’s name, form, taste, appearance, in other word everything that can be 
perceived by them and can make it easy or difficult for them to carry out pharmacological 
therapy.  
Danger of misunderstanding and improper use of pharmaceuticals can have serious 
consequences. As pointed out by Aarseth (2001), significant number of patients in general 
wards are hospitalized because of side effects or incorrect use of pharmaceuticals. For these 
reasons, patient’s adherence is crucial. 
According to the NICE clinical guideline 
xi, adherence is defined as “the extent to which the 
patient’s action matches the agreed recommendations”, thus it primarily requires a consensus 
between the patient and the prescriber about the use of medication. According to the Guide 
xi 
, 
non-adherence is therefore seen as a basic limitation in delivery of health care, and not merely 
the patient’s problem. This initial consensus requires the patient’s involvement in the decision 
to prescribe and access to information and support from the health provider’s side, i.e. both 
from the prescriber and the pharmacist dispensing the medicine. 
Opponents of generic substitution often argue that a patient can receive the same substance, 
but with different name, appearance and dosing schedule on each visit to the pharmacy 
(Solanki, 2009), which can leave them confused. The problem is particularly pronounced for 
elderly patients or/and those who suffer from chronic conditions. Older people take often 
several drugs, and it is harder for them to stick to their regiments thus they are more likely to 
have an adverse drug reaction. In a study quoted by Solanki (2009), over 30% of elderly (60 
years and over) patients prescribed antidepressants, were on drug regiments of at least eight 
different pharmaceuticals. Some of the patients were taking as many as 20 different drugs 
daily. For obvious reasons such patients develop their administration routines, based on 
appearance of the medicines as well as on their packaging. In case of older patients, the 
correct use of medicines can be also sabotaged by poor eyesight and confusion. This can 





The recent Norwegian study (Håkonsen and Toverud, 2011) discovered that as many as 10% 
of the studied patient population (Pakistani immigrants in Oslo on long-term medicines), were 
mistakenly using more than one equivalent generic preparations at the same time. The 
incorrect use of medicines was more likely for patients who used more than one pharmacy 
and those who had problems with receiving complete information about the dispensed 
pharmaceuticals.  
The simplest way to improve compliance among patients is to ensure good communication, 
which should flow in both directions. Most patients want to be involved in the decision-
making process, and the more involved they are the better understanding of their own therapy 
they have; the more likely they are to comply with it. Good doctor-patient relationship and 
clear written instructions also improve patients’ adherence (MERC, 1997).  
To counteract the dangers or non-compliance, NoMA requires the products within the same 
substitution groups, apart from the same strength, to have the same pharmaceutical form (oral 
tablets/capsules can be only substituted by oral tablets/capsules) and approximately the same 
size of the packaging (though small variations are acceptable). The scheme also gives 
prescribers the right to reservation against automatic substitution. This is possible when 
doctors predict a high probability for the individual patients’ non-compliance. 
 
4.3.2 Bioavailability 
Another argument of the antagonists of generic substitution is varying bioavailability.  
According to the European Medicines Agency (EMEA/CPMP: 2001), bioavailability of 
generics has to lie between 80% and 125% of the original branded medicine. This means 
potentially that patients, who are being often switched between different generic medicines, 
could receive a medicine with 125% bioavailability on one occasion, and 80% on the next. 
This would mean a 36% loss in bioavailability. If the patient were switched back to the 125% 
bioavailability medicine, they would experience a 45% increase in bioavailability. Such a 
change can affect the clinical outcomes for the patient. Meredith’s study (2003) emphasizes 




very narrow or very broad therapeutic range especially when confronted with high subject 
variability (both between different subjects and within the same subject).   
However bioequivalence studies quoted by Madsen et al. (2008) show that, the variation in 
bioequivalence is most often less than 3%. Such differences have no clinical effect and are 
smaller than variation naturally found within the same subjects, which can be as high as 60% 
from one day to another. 
The MERC manual (MERC, 1997) also confirms that the actual differences in bioequivalence 
between generic and trade-name drugs approved by FDA (The US Food and Drug 
Administration), are on average 3.5% and rarely exceed 10% in any single study. 
4.3.3 Changed effect and adverse effects 
Another problem often raised in the debate on generic substitution is the issue of changed 
effect and adverse effects (Madsen et al. 2008). It is claimed that non-active substances in 
generic preparations can cause allergic reactions and that the medicine itself causes different 
effects than the original drugs.  
Despite scarce documentation and evidence of the side effects, a Norwegian study exploring 
patients’ attitudes towards generics 3 years after introduction of the generic substitution  
(Kjønniksen et al. 2006), found that every third patient who had their medicine substituted 
reported negative experiences. 
The NoMA registers and evaluates each report of side effects. As argued by Madsen et al. 
(2008), after examining 400 reports of incidents of adverse effects, NoMA found no evidence 
of serious adverse effects, which would be due to the preparation itself.  This suggests that 
problems arise mainly due to the incorrect use of medication rather than the drug’s 
composition. 
The system also gives prescribers the right to reserve against generic substitution, in case 






4.3.4 Believes and attitudes 
Finally, there come arguments from outside of the scientific world. According to the German 
study by Himmel (2005), over one-third of the patients who declared they knew the difference 
between the branded-name and generic products, were skeptical towards generic because of 
their lower price. Some of the questioned patients were convinced that generic prescribing 
was “invented” to solve financial problems of the insurer on the patients’ expense (Himmel, 
2005). The German patient population is not isolated in the way they perceive generic 
medications. The results of the Norwegian study (Kjønniksen et al. 2006) quoted earlier, also 
suggest that psychological factors and prejudices can play significant role. Many people are 
convinced that lower price equals lower quality. One quarter of the patients interviewed for 
the Håkonsen’s and Toverud’s study (2011), expressed an opinion that generic alternatives 
were counterfeit drugs and their effects were poorer.  
An earlier study by Håkonsen et al. (2009) indicated that patients’ negative attitude towards 
generics were strongly associated with number of drugs used, education level and insufficient 
information concerning substitution. 
Researchers agree that an individual approach, providing thorough and comprehensive 
information on medications by prescribers to their patients is fundamental. It can help to 




The present study aims at examining and determining potential predictors of variation in 
doctors’ reservation level across different substances. Although the author appreciates the 
underlying reasons based on true medical considerations as well as those based on believes,  
the performed analyses focuses on economical (non-medical) and geographical determinants 
of prevalence in doctors’ reservation notes.  In particular the influence of pharmaceutical 
prices raised both by Lundin (2000) and Furu et al. (2008), (though in wider context of 
prescribing decisions), is going to be tested in this thesis in the specific context of doctors’ 




The recent study on NorPD data (Furu et al. 2008 and Dalen et al., 2011) including 23 
different substances (both reimbursable and non-reimbursable prescription drugs); found that 
patients are more likely to end up with generic products when the price difference between the 
original and generic alternatives increases. However the authors discovered also that patients 
who have their medication reimbursed (those with the so-called “blue prescription”) are more 
likely to choose the brand name preparation. 
These results suggest that generally the price difference does matter, but its effect can be 
somewhat slowed down by the type of prescription (reimbursable vs. non-reimbursable). 
The present thesis uses data on reimbursable drugs only and is going to test if the price 
difference can impact the proportion of reservation notes made by doctors. In other words, the 
author seeks to find out if doctors are sensitive to their patients’ preferences/requests 
motivated economically. In particular, I hypothesize that the larger the price difference is, the 
more likely it is that the physician makes a reservation to save the patient from extra 
expenses.   
In addition, some of other variables will be tested as potential predictors. Pharmacy chains 
(similarly to the study by Furu et al 2008), level of centrality (geographical location of 
dispensing pharmacy), type of pharmaceutical and their association with the level of doctors’ 











5. METHODS AND DATA 
 
 5.1 Study design 
Cross-sectional numerical data derived from two extensive datasets (The National 
Prescription Database in Norway and pharmacy reservation reports) was gathered, merged, 
aggregated and prepared for statistical analysis using descriptive statistics and binary logistic 
regression. Time periods selected included: June 2006, June 2007, June 2008, June 2009 and 
June 2010; and covered the set of 9 selected substances, making up 23 substitution groups. 
The obtained dataset includes monthly records from all community pharmacies (hospital 
pharmacies were not included) in Norway, covering a number of variables (listed in a section 
below) and aggregated at  the level of municipalities and pharmacy chains. 
A mini focus group with 6 general practitioners from Eastern Oslo area was also performed to 
obtain professional opinions about the hypotheses, as well as to capture observations and 
attitudes towards generic substitution and doctors’ role in the scheme. Another mini focus 
group with representatives of the three biggest pharmacy wholesalers was organized in the 
final stage of the study to obtain their comments on the results. The results were also 
presented at the NoMA Department of Pharmaco-economics and the Department of Medical 




The National Prescription Database in Norway (Nor PD) was established on 1 January 2004 
to gather data on the use of prescription-only drugs (POD). The Norwegian Institute of Public 
Health (FHI) has been since in charge of running the register. The main idea behind starting 
the database was to improve knowledge about the use of pharmaceuticals as well as 
describing characteristics of both prescribers and users, thus raising the rational use of 






NorPD contains data on prescription drugs dispensed from all Norwegian primary pharmacies 
on monthly basis. It does not include the sales of over-the-counter drugs (OTC). Pharmacies 
register the data electronically and the information is made anonymous on the individual 
doctor’s and patient’s level. Identity numbers of patients or their doctors are replaced with 
sequence numbers (pseudonyms).  This allows maintaining the link between prescription and 
these individuals without abusing their privacy. Even though one person could have a 
medication prescribed more than once, the medication will be calculated according to their 
real number, while the user will be counted only once. 
The data is registered on an individual level and include characteristics of the user, 
medication, prescriber and these of the dispensing pharmacy. The following table presents the 
information registered in NorPD. 
Table 10. Data registered in NorPD 
Data level Data registered in NorPD 
User Pseudonym (sequence number), year and month of birth, 
gender, municipality 
Medication Item number, number of packages, refund section, price, price 
proportion paid by user, date for dispensing 
Prescriber Pseudonym (sequence number), year of birth, gender, 
profession, specialization 
Pharmacy License number, municipality 
Source: Based on the information on NorPD by FHI xiv 
 A number of reports derived from NorPD are readily available to the population, such as: 
number of users of particular substances (also by gender and age group, region or county), 
prevalence use per 1000 inhabitants, sales values in NOK, sales volume in DDDs (Defined 
Daily Doses, term defined below).  
Data on reservations (both those made by doctors and by patients) come from monthly reports 
from pharmacies to FHI. The data is aggregated on the level of individual pharmacies per 





For the present analyses, NorPD and reservation records for nine substances across three 
indication groups, included in the stepped price system, were chosen. The table below 
presents the substances selected. Each of them is coded according to the ATC (Anatomical 
Therapeutic Chemical) classification system. These nine substances are subject to further 
classification into 23 substitution groups. The initial raw data contained information 
aggregated on the municipality and pharmacy chain level reported in June for years 2006-
2010 (5 time points) for every product containing any of the 9 active substances dispensed.  
The dataset included 66 489 observations (rows) across 36 variables (columns). There were 
10 637 observations for 2006, 12 312 for 2007, 13 351 for 2008, 13 897 for 2009 and 16 292 
observations for 2010. Numerical data crucial for performing the statistical analyses was 
either originally expressed or re-calculated by the author into the common unit – Defined 
Daily Doses (DDDs). Below the concepts of ATC classification system, substitution groups 
and Defined Daily Doses are defined more in detail. 
Table 11. Selected substances by indication and inclusion in substitution list 
ATC  code Active agent Class Main indication 
Included in the stepped-
price system/substitution 
scheme * 
A02BC01  omeprazole  PPI  Gastric ulcer Before 2004 
A02BC02 pantoprazole  PPI  Gastric ulcer 01/12/2007 
A02BC03 lansoprazole PPI  Gastric ulcer 01/05/2005 
A02BA02 ranitidine 
H2-receptor 
antagonists  Gastric ulcer 
 
Before 2004 
C10AA01 simvastatin HMG CoA reductase  High cholesterol Before 2004 
C10AA03 pravastatin HMG CoA reductase  High cholesterol 15/10/2004 
N06AB04 citalopram SSRI  Depression Before 2004 
N06AB05 paroxetine SSRI  Depression 01/05/2004 
N06AB10 escitalopram SSRI  Depression 01/03/2010 
PPI= Proton pump inhibitor, SSRI= Selective Serotonin Reuptake Inhibitor 




5.3.1 Anatomical Therapeutic Chemical (ATC) Classification System 
The Anatomical Therapeutic Chemical (ATC) Classification System is used for the 
classification of pharmaceuticals. It is controlled by the WHO Collaborating Centre for Drug 
Statistics Methodology (WHOCC), and was first published in 1976. In the ATC system the 
drug substances are classified into groups at 5 different levels. The classification system 
divides drugs into different groups according to target organ of the system, mechanism of 
action, and chemical and therapeutic properties. Each bottom-level ATC code stands for a 
pharmaceutically used substance in a single indication (or use).  The drugs are divided into 
fourteen main groups (1st level), with one pharmacological/ therapeutic sub-group (2
nd
 level).  
The 3rd and 4th levels are chemical/pharmacological/ therapeutic sub-groups and the 5th level 
is the chemical substance. (Legemiddelstatistikk 2010:2 • Folkehelseinstituttet). 
Table 12. ATC groups 
ATC main groups Main therapeutic/indication area 
ATC group A Alimentary tract and metabolism 
ATC group B Blood and bloodforming organs 
ATC group C Cardiovascular system 
ATC group D Dermatologicals 
ATC group G Genito - urinary system and sex hormones 
ATC group H Systemic hormonal preparations, excl. sex hormones and insulins 
ATC group L Anti-neoplastic and immunomodulating agents 
ATC group M Musculo-skeletal system 
ATC group N Nervous system 
ATC group P Anti-parasitic products, insecticides and repellents 
ATC group R Respiratory system 
ATC group S Sensory organs 








5.3.2 Substitution groups 
The NoMA publishes a substitution list which includes interchangeable medicines. Each 
product is assigned to the relevant substitution group. Pharmaceuticals must be approved as 
equivalent and interchangeable to be classified within the same substitution group. In practice 
it means that apart from containing the same active substance they have to be of the same 
strength and the same form of administration, i.e. pills can be only interchangeable with pills 
and dissolvable tablets with dissolvable tablets. Each active substance (each ATC code) can 
be represented by one or more substitution groups, only of different strengths or forms. 
Within one substitution group there can be brand-name products, generic versions of the 
original medicine or products coming from parallel import, all with the individual product 
number. Each of the substitution groups is assigned the stepped price by NoMA, and the 
pharmacies are obliged to have at least one preparation within each substitution group 
available at the stepped price. The catalogue of substitution groups chosen for these analyses 
can be viewed in the appendix. 
 
5.3.3 Defined Daily Doses (DDDs) 
Defined daily doses (DDDs) are a statistical measure of drug consumption established by 
WHO and used internationally. DDDs are used to standardize the comparative usage of 
various drugs between themselves or between different health care environments. 
Norwegian Prescription Database defines a DDD as “the assumed average maintenance dose 
per day for a drug used for its main indication in adults. It is important to be aware that in 
many cases the prescribed dose may deviate from the DDD. The DDD should only be 
considered as a technical unit of measurement.” xiv. Using DDDs allows for comparison 
between alternative medications, regardless of price differences. In addition, the evaluation of 
drug consumption volumes over time, nationally and internationally, is simplified and 
improved by the use of DDDs. The DDDs are determined on the basis of evaluation of 
international use of the substance in question, bearing in mind that national therapy traditions 
(indications, dosages) often differ greatly. Drugs used for more than one indication may cause 




DDDs. With the exception of a very few specially formulated pediatric preparations, adult 




 5.4 Variables  
As mentioned above, the dataset includes 66 489 observations (rows) across 36 variables 
(columns), specifying (among others): date, municipality, county, level of centralization, 
pharmacy chain, product code, packing description, ATC code, administration form, strength,  
number of DDDs per packing, prescription group, substitution group number, original vs. 
generic, turnover in number of packages, doctor’s reservation in packages, patient’s 
reservation in packages, turnover in DDDs, doctor’s reservation in DDDs, patient’s 
reservation in DDDs, sales in PRP, value covered by the patient in PRP, price PRP, part of 
PRP covered by patient, maximum PRP, stepped price. 
5.4.1 Dependent variable 
The doctors’ reservation level in DDDs, labeled as “DocRes” is in the centre of all the 
analyses performed. It has been calculated as a proportion of doctors’ reservation in DDDs to 
turnover in DDDs. The results obtained were numbers within the interval [0;1] for the great 
majority of the rows, except for 212 outliers (22 values below 0 and 190 values greater than 
1). Since the outliers represented only 0.31 % of all 66 489 observations, the author decided to 
keep the outliers in the dataset, as they were values as reported from the pharmacies and they 
might have reflected some corrections in reporting on sales/reservations. For the analyses 
using descriptive statistics it was necessary to weigh the obtained observations by the 
corresponding turnover in DDDs. In this way the aggregation was represented in every 
observation and the real means could be calculated.  
5.4.2 Independent variables  
“Delta” – continuous variable, representing the price difference between branded and generic 




The construction of this independent variable is crucial for the analysis of the influence of 
economic incentives in the model and was extensively discussed (among the author and the 
supervisors). The price difference has been calculated by deducting the stepped price from the 
maximum retail price (PRP). In this case only that price difference is relevant because the 
usual patient’s co-payment (before 2011 = 36%) would be the same for all the three following 
scenarios, but the effective expense would only be different if they opposed the substitution 
without doctor’s reservation: 
1. The patient accepts generic substitution – the patient pays the usual co-payment (36% 
of the stepped price, which can be entered into their co-payment card for reimbursable 
drugs) 
2. The patient gets the original medication with the doctor’s reservation on it – the 
patient still pays only the usual co-payment 
3. The patient rejects substitution and agrees to cover the difference him/herself 
(patient’s reservation) – the patient has to pay the usual co-payment and cover the 
price difference between the price of the original preparation and the stepped price 
Therefore the only factor influencing the doctors’ (and their patients’) decision on the final 
choice (also about making a reservation or persuading the doctor to make one) would be the 
additional price difference, that would have to be covered out of the patient’s pocket. 
Although the real prices may vary across pharmacy chains, the figures for the reimbursed 
portion of cost remain the same across the pharmacies, and as such are available for doctors to 
view via the catalogue. 
Pharmacy chain – categorical variable covering five categories, coded in the following way: 
AP1 - Apotek 1 coded as 1, VAP –Vitus Apotek, coded as 2, BAP – Boots Apotek coded as 
3, DAP - Ditt Apotek coded as 4, UDA – independent pharmacies, coded as 5. For AP1, VAP, 
DAP, and UDA dummy variables were created. BAP served as the reference (baseline) 
category. 
ATC codes – representing the three selected pharmaceutical groups - categorical variable 




statins- 2, N* - antidepressants – 3. Dummy variables were created for anti-acid and anti-
depressive drug categories, leaving statins to serve as the reference group. 
Level of centralization – categorical variable standardized and used by the Statistics Norway 
(Statistisk Sentralbyrå), describing the geographic location of a municipality in relation to 
urban settlements of various sizes. The urban settlements are divided into three levels 
according to population and available public services. Urban settlements at level 3 are 
regional centers (population at least 50 000), level 2 settlements have a population between 15 
000 and 50 000, and level 1 settlements have a population between 5 000 and 15 000. To 
describe the available alternatives for work travels to one or several urban settlements, the 
municipalities are divided into four centrality levels 
xv
:  
 Sentrale kommuner (urban municipalities) – Central municipalities that include an 
urban settlement at level 3 (regional centre) or are within 75 minutes (90 minutes 
for Oslo) travel from the centre of an urban settlement (central municipalities) – in 
the present analyses coded as 1 
 Noe sentrale kommuner (smaller urban municipalities) – Fairly central 
municipalities that include an urban settlement at level 2 or are within 60 minutes 
travel from the centre of an urban settlement – in the present analyses coded as 2 
 Mindre sentrale kommuner (less central municipalities) – includes fairly remote 
municipalities that include an urban settlement at level 1 or are within 45 minutes 
travel from the centre of an urban settlement – in the present analyses coded as 3 
 Minst sentrale kommuner (least central municipalities) - includes remote 
municipalities  that do not meet the requirements for travel time from urban 
settlement – in the present analyses coded as 4 
 
If a municipality fulfills the requirements to centrality on more than one level, the highest of 
these levels applies. 
Dummy variables were created for urban municipalities, less central and the least central 




5.5 Statistical tools and analyses  
PASW Statistics (formerly SPSS) version 18 was used to perform the quantitative analyses of 
the dataset. 
 
5.5.1 Descriptive statistics 
The analysis of the distribution of the dependent variable (DocRes) was performed using 
histogram and descriptive statistics. Weights of the corresponding turnover values in DDDs 
were applied to reflect the aggregation hidden in each individual row (observation). As the 
result 71 842 471 DDDs were obtained from 66 489 rows of aggregated original reports. 
The analyses of frequencies and histograms were also performed separately for each of the 
periods. The obtained distributions for doctors’ reservation level (both weighted and non-
weighted) proved to be far from normal, with large variations, substantial difference between 
mean and median, with the median value equal to zero. The attempts towards “normalizing” 
of the distribution were not successful. The table below presents basic descriptive for the 
variable.  
Table 13. Basic descriptive statistics and histogram for DocRes 
 
* Values from outside the [0, 1] interval are result of the occurrence of outliers discussed above 
Doctors' reservation 
level 












In addition descriptive statistics for DocRes have been run across all of the independent 
variables to provide an overview of variation and base for analyses using logistic regression. 
The next chapter contains relevant tables and description of the findings.  
 
5.5.2 Binary Logistic Regression 
 
The author has decided that using the binary logistic regression will be the most appropriate 
(compared with, for example, a linear regression) for of analyses for the following reasons: 
 The distribution of the dependent variable – doctors’ reservation level (DocRes) is far 
from being normal (alternative use of linear regression would produce unreliable 
results), 
 The dependent variable (DocRes) is a proportion, which takes values in the range 0.0 
to 1.0 representing probability values. It would be illogical to try to extrapolate values 
beyond this interval. 
It is important to note, that due to the choice of binary logistic regression, the independent 
variable changes its character from being continuous within the interval [0; 1] into becoming 
binary with values either 0 or 1. Therefore each line representing so far the aggregated 
monthly data from each pharmacy chain for each municipality becomes equally weighted 
individual report case coded for either presence or absence of doctors’ reservation notes. 
This type of variable is called a Bernoulli (or binary) variable, as only two types of outcomes 
are possible: the doctor makes a reservation note or he/she does not. Proportions and 
probabilities are different from continuous variables in a number of ways. They are bounded 
by 0 and 1, whereas in theory continuous variables can take any value between plus or minus 
infinity. This means that normality for a proportion cannot be assumed, and therefore a 
binomial distribution has to be assigned. Unlike the normal distribution, the mean and 
variance of the Binomial distribution are not independent. The mean is denoted by P and the 
variance is denoted by P*(1-P)/n, where n is the number of observations, and P is the 
probability of the event occurring (e.g. the probability of doctors’ making a reservation note). 
Since logistic regression calculates the probability or success over the probability of failure, 




Odds = p/(1-p),  
The logarithm of p/(1-p) is called the logit, and maps probabilities onto the scale of the linear 
predictor in logistic regression. The log odds is the logarithm of the odds of the probabilities 
(Pallant, 2007). 
Like ordinary regression, logistic regression can be extended to incorporate more than one 
explanatory variable, which may be either quantitative or qualitative. The logistic regression 
model can then be written as follows (Bewick et al. 2005): 
logit(p) = a + b1x1 + b2x2 + … + bixi 
where p is the probability of doctors making a reservation note on prescription and x1, x2 … 
xi are the explanatory variables (predictors). 
Applying logistic regression with the assumptions of a large sample size and absence of 
multicollinearity among the predictors (independent variables) can provide answers to 
questions such as which variables are important in determining whether a doctor makes a 
reservation note or not.  
The large sample size requirement is fulfilled thanks to the extensiveness of the dataset. Since 
there is no formal way in the logistic regression to test for multicollinearity in SPSS (Pallant, 
2007) and the predictors (independent variables) are very few and representing very distinct 
categories, the author is assuming absence of multicollinearity among them. 
For performance of the binary logistic regression procedure, it was necessary to introduce a 
modified dependent variable (BinaryDocRes) with two possible values: 0 for the lines when 
doctors’ reservation did not occur at all (DocRes = 0), and 1 for all positive values of DocRes 
(DocRes > 0).  
Five binary logistic regressions were performed separately for each of the five periods, 
introducing BinaryDocRes as the dependent variable and the following variables as 
predictors: delta, centralization (along with 3 dummies), pharmaceutical group (2 dummies) 
and pharmacy chain (4 dummies). The reference group was made up of records for the 
reservation level for statins sold by the Boots pharmacy in a smaller urban municipality. The 
separate analyses for individual categories of pharmaceuticals as well as a regression with 































6.1 Descriptive statistics 
Mean doctors’ reservation levels have been calculated across all of the independent variables 
and presented below. It has been noted that there might have been a problem with the data for 
2008, as the doctors’ reservation level is consistently lower across all independent variables 
than in remaining periods. The author has attempted to find the reason (with the help of 
NoMA), however no explanation was found. Since the results for 2008 are not contradictory 
to the trends for the four other periods, the 2008 data was included in the analyses. 
Delta 
The table contains “Delta” values - the price differences between branded and generic 
preparations within the same substitution group, expressed in NOK/DDD for all five periods 
(June  2006-2010) across all 23 substitution groups as well as corresponding mean doctors’ 
reservation level (DocRes) reported within these groups for the same point of measurement. 
One can observe a big variation in DocRes, both among different pharmaceutical groups, as 
well as within the groups themselves. For example, among the acid suppressing drugs some 
preparations (Ranitidin) have DocRes below 1% while others (Omeprazol) oscillate on the 
level of 25-42%. Such differences can also be observed among statins: Simvastatin (DocRes 
at 5%) vs. Pravastatin (15.5%) and antidepressants: Escitalopram (2-4%) vs. Paroksetin – 
13%. However, it is difficult to match it with the variability in “delta”. For some of the 
highest values of DocRes, “delta” can be either relatively high or, on the contrary, lie in the 
lower  range of “delta” values. There seems to be no obvious correlation between the “delta” 
values and the corresponding DocRes proportions. These results will be tested further with the 











Table 14.  Mean price differences (delta) vs. mean doctors’ reservation levels, years 2006-2010




2008 Δ 2009 Δ 2010 D.Res'06 D.Res'07 D.Res'08 D.Res'09 D.Res'10 
A02BA02 000012 RANITIDIN BRUSETABLETTER 150MG* 0,00 0,00 0,00 0,00 0,00 0,0325 0,0271 0,0000 0,0000 0,0000 
A02BA02 000013 RANITIDIN TABLETTER 150MG 0,00 0,00 0,00 0,51 0,51 0,0210 0,0163 0,0010 0,0027 0,0013 
A02BA02 000014 RANITIDIN TABLETTER 300MG 0,00 0,00 0,00 0,00 0,00 0,0311 0,0210 0,0003 0,0011 0,0001 
A02BA02 000015 RANITIDIN BRUSETABLETTER 300MG 0,00 0,00 0,00 0,03 0,03 0,0252 0,0180 0,0000 0,0000 0,0000 
A02BC01 000023 OMEPRAZOL TABLETTER 10MG** 6,57 4,45 7,88 7,78 3,36 0,3790 0,5144 0,4189 0,4681 0,4234 
A02BC01 000024 OMEPRAZOL TABLETTER 20MG 6,25 5,22 4,81 3,41 1,16 0,2110 0,2600 0,2616 0,2648 0,2547 
A02BC02 001420 PANTOPRAZOL ENTEROTAB  40 MG****     5,83 5,79 5,89     0,0154 0,0044 0,0017 
A02BC02 001525 PANTOPRAZOL ENTEROTAB 20 MG****     5,84 5,76 4,76     0,0037 0,0032 0,0014 
A02BC03 000028 LANSOPRAZOL ENTEROKAPSLER 30MG*** 7,95 8,60 7,83 7,46 10,27 0,0123 0,0143 0,0018 0,0031 0,0015 
A02BC03 000938 LANSOPRAZOL ENTEROKAPSLER 15MG*** 9,40 10,47 8,54 7,90 8,04 0,0084 0,0105 0,0003 0,0018 0,0023 
C10AA01 000251 SIMVASTATIN TABLETTER 10MG 0,00 0,00 0,00 3,99 4,62 0,0411 0,0354 0,0007 0,0435 0,0545 
C10AA01 000252 SIMVASTATIN TABLETTER 20MG 0,00 0,00 0,00 4,20 1,56 0,0362 0,0342 0,0007 0,0407 0,0434 
C10AA01 000253 SIMVASTATIN TABLETTER 40MG 0,00 0,00 0,00 2,45 2,10 0,0351 0,0417 0,0006 0,0363 0,0401 
C10AA01 000254 SIMVASTATIN TABLETTER 80MG 0,00 0,00 0,00 3,00 2,72 0,0389 0,0698 0,0006 0,0551 0,0607 
C10AA03 000261 PRAVASTATIN TABLETTER 20MG 6,22 7,42 7,64 10,16 7,54 0,1122 0,1717 0,1482 0,1465 0,1404 
C10AA03 000853 PRAVASTATIN TABLETTER 40MG 5,79 5,45 6,29 5,44 4,74 0,1447 0,1535 0,1601 0,1642 0,1704 
N06AB04 000656 CITALOPRAM TABLETTER 10MG 6,69 7,44 7,56 7,66 6,23 0,0631 0,0806 0,0346 0,0685 0,0514 
N06AB04 000657 CITALOPRAM TABLETTER 20MG 4,15 4,61 4,68 3,66 3,53 0,1019 0,1043 0,0959 0,1085 0,1043 
N06AB04 000658 CITALOPRAM TABLETTER 40MG 3,90 4,27 4,20 3,97 3,47 0,0200 0,0000 0,0000 0,0000 0,0000 
N06AB05 000661 PAROKSETIN TABLETTER 20MG 2,43 2,53 2,16 2,15 0,96 0,0942 0,0906 0,0832 0,1436 0,1377 
N06AB10 000671 ESCITALOPRAM TABLETTER 10MG***** 1,38 1,30 2,31 2,48 2,36 0,0000 0,0000 0,0000 0,0000 0,0313 
N06AB10 001651 ESCITALOPRAM TABLETTER 5MG*****         2,86         0,0271 




































*Only original has been available on the market 
**Usually prescribed to children 
*** Original not available on the market 
****Original (Somac) available at stepped price at all pharmacy chains 
***** Original (Cipralex) available at stepped price at one of the pharmacy chains in 2010 
 
Pharmacy chain 
There is a noticeable variation in DocRes across different pharmacy chains, with substantial 
differences between the maximum and minimum values. See the table below.  
 
Table 15. Level of doctors’ reservations by pharmacy chain, years 2006-2010 
  2006 Std.dev. 2007 Std.dev. 2008 Std.dev. 2009 Std.dev. 2010 Std.dev. 
APOTEK 1 0,0578 0,1915 0,0577 0,1918 0,0297 0,1578 0,0534 0,1926 0,0504 0,1974 
BOOTS APOTEK 0,0616 0,1561 0,0679 0,1831 0,0282 0,1666 0,0595 0,2050 0,0613 0,2125 
DITT APOTEK 0,0483 0,2024 0,0547 0,1794 0,0268 0,1570 0,0429 0,2153 0,0527 0,2134 
OTHER 0,0416 0,1715 0,0367 0,1846 0,0230 0,1547 0,0455 0,1870 0,0638 0,2068 
VITUS 0,0429 0,1690 0,0551 0,1584 0,0306 0,1373 0,0517 0,1929 0,0622 0,2153 
MEAN 0,0543 0,1852 0,0587 0,1857 0,0293 0,1594 0,0536 0,2008 0,0564 0,2060 
 
However these differences show also some dynamics in terms of internal results for individual 
chains throughout different years, as well as ranks that the pharmacy chains take in 
comparison with their competitors (see the Chart below). For example, independent 
pharmacies (category: other) had in the first four years the DecRes in the lowest range, and 








Chart 5. Level of doctors’ reservations by pharmacy chain, years 2006-2010 
 
 
Level of centralization 
 
There is a considerable variation in the level of doctors’ reservation, and more importantly, 




Table 16. Level of doctors’ reservations by centrality level, years 2006-2010 
 
  2006 Std.dev. 2007 Std.dev. 2008 Std.dev. 2009 Std.dev. 2010 Std.dev. 
Urban 0,0566 0,1852 0,0606 0,1862 0,0320 0,1665 0,0593 0,2099 0,0612 0,1945 
Smaller urban 0,0536 0,1846 0,0608 0,1889 0,0258 0,1478 0,0476 0,1886 0,0528 0,1842 
Less centralized 0,0454 0,1789 0,0447 0,1683 0,0210 0,1332 0,0341 0,1585 0,0385 0,1630 
Least centralized 0,0450 0,1906 0,0516 0,1885 0,0229 0,1499 0,0418 0,1882 0,0475 0,1850 
 
Urban and smaller urban municipalities clearly score highest on the reservation level, while 

















Acid-modifying drugs show consistently the highest level of doctors’ reservations when 
compared with the two other selected pharmaceutical groups. Moreover, this difference 
presents as substantial, though appears to be a bit smaller in the last year of the analysis. 
 
Table 17. Level of doctors’ reservations by ATC gruop, years 2006-2010 
ATC code 2006 Std.dev. 2007 Std.dev. 2008 Std.dev. 2009 Std.dev. 2010 Std.dev. 
antiacid 0,0859 0,2550 0,1095 0,2868 0,0795 0,2542 0,0764 0,2527 0,0686 0,2370 
statins 0,0476 0,1520 0,0514 0,1476 0,0107 0,0984 0,0472 0,1797 0,0507 0,1972 
antidepressant 0,0519 0,2023 0,0468 0,1877 0,0387 0,1815 0,0502 0,2013 0,0598 0,1965 










Chart 7. Level of doctors’ reservations by ATC gruop, years 2006-2010 
 
 
6.2 Logistic regression 
Binary logistic regression was performed separately for each of the five time points, as well as 
for pooled data for all periods, to assess the impact of the independent variables on the 
likelihood that doctors make a reservation note on a prescription. As mentioned previously, a 
modified version of the dependent variable (BinaryDocRes) had to be introduced. The new 
BinaryDocRes can take only one of the two possible values: 0 for the lines when doctors’ 
reservation did not occur at all (DocRes = 0), and 1 for all positive values of DocRes (DocRes 
> 0).  
















*p < 0.1; **p < 0.05; ***p < 0.001. Baseline: Statins dispensed at Boots pharmacy in smaller urban centres 
















  Predictor B Sig. Exp(B) B Sig. Exp(B) B Sig. Exp(B) B Sig. Exp(B) B Sig. Exp(B) 
Delta .070*** .000 1.073 .036*** .000 1.037 .000*** .000 1.000 -.001*** .000 .999 -.001*** .000 .999 
urban(1) .191** .002 1.210 .218*** .000 1.244 .193** .005 1.212 .300*** .000 1.350 .139** .007 1.149 
less_centralized(1) -.191* .065 .826 -.071 .433 .931 -.208* .067 .812 -.054 .564 .947 -.251** .004 .778 
least_centralized(1) -.199** .021 .820 -.229** .005 .795 -.271** .007 .762 -.133 .104 .876 -.196** .006 .822 
AP1(1) -.260*** .000 .771 -.155** .008 .856 .344*** .000 1.411 -.415*** .000 .660 -.140** .014 .869 
VAP(1) -.043 .563 .958 -.019 .771 .981 .050 .530 1.052 -.072 .300 .931 -.157** .008 .855 
DAP(1) -.100 .324 .905 .044 .641 1.045 -.176 .195 .838 -.145 .210 .865 -.176* .077 .839 
OTHER(1) -.265* .072 .767 -.348** .006 .706 -.163 .285 .850 -.304** .009 .738 -.106* .278 .899 
antiacid(1) 1.263*** .000 3.535 1.257*** .000 3.516 -.303*** .000 .739 1.707*** .000 5.513 1.711*** .000 5.535 
antidepressants(1) .757*** .000 2.132 -.716*** .000   2.047 -.492*** .000 .612 .703*** .000 2.020 .612*** .000 1.845 








The model contained one continuous independent variable: delta - the price difference 
between branded and generic preparations within the same substitution (variable entered 
without modifications), and three categorical variables: centrality level, pharmacy chain, 
pharmaceutical group (variables entered as dummies). The reference group was made up of 
records for reservation level for statins sold by the Boots pharmacy in a smaller urban 
municipality. Due to the utilization of dummy variables the coefficient values on individual 
categorical variables need to be interpreted as relative to their reference (baseline) groups. 
The reference group for all five periods tested is the same. 
The main results have been gathered in the table below. The complete PASW output can be 
viewed in the appendix. 
All five logistic regression analyses run on the full set of independent variables (predictors) 
for the years 2006-2010 scored significant ( .000, which really means p < 0.0005 ) on the 
Omnibus test of model coefficients. This test challenges goodness of fit test and shows how 
well the model performs without predictors entered into the model (Omnibus tables with Chi-
square values for each regression available in the appendix with PASW output). Since the test 
proved to be significant for all five regressions, one can conclude that the model built was 
able to distinguish between cases where doctors’ reservation did occur and where it did not 
occur. The model had a varied explanatory power for different years (see model summaries in 
the appendix with PASW output), and for example, in 2010 explained between 9.6% (Cox 
and Snell R square) and 15.3% (Nagelkerke R square) of the variance in reservations’ 
proportion.  
B values – values in the equation. Negative values mean that an increase in the independent 
variable score will result in the decreased probability of the case reporting a score of 1 
(doctors’ making a reservation note).  
The Exp (B) columns show values for odd ratios (OR) for each of the independent variables. 
Odd ratio is a relative measure of probability that an event occurs to that it does not occur. 
Odd ratios represent the change in odds of being in one of the categories of outcomes relative 
to the other, when the value of a predictor increases by one unit (Pallant, 2007). For example, 




reserving note is a little higher (1.149 times higher) for urban areas than for the reference 
group (here the smaller urban areas), all factors being equal. 
Below, the main findings across all independent variables are discussed. 
Delta 
As indicated in the analysis of descriptive statistics, it is difficult to draw any ultimate 
conclusions about dependence of DocRes on the delta. For the first year of the analysis 
(2006), a 1 NOK/DDD of increase in difference in prices between original and generic 
medicines, resulted in the odds ratio that the reservation will occur being equal to 1.073 (a 
slight increase in likelihood that doctors decide to guard against substitution). The following 
period this effect was even weaker (Exp (B) = 1.037), then there was no effect at all, and for 
the last two periods there is an extremely small negative effect. Although regression 
coefficients proved significant (p < 0.001) for all five periods, the effect size is predominantly 
very small, for all of them and the direction of the effect is very inconsistent (positive for the 
first two periods and negative for the two last periods). The results for pooled analyses for all 
five periods was consistent with the findings for individual time periods, ie. (Exp (B) = 0.999, 
p < 0.001). 
The author chooses to remain skeptical towards calling the association meaningful, and 
concludes that the price difference between original preparation and its generic counterpart 
does not have a direct influence on the doctors’ reservations level. 
Pharmacy chain 
As observed in the descriptive part, there is a variation in DocRes among different pharmacy 
chains. In the logistic regression analysis, some of these differences proved significant, some 
did not. The level of Doc Res for Apotek1 (AP1) was significantly lower (odds ratio from 
0.66 in 2009 to 0.869 in 2010), apart from 2008 (OR: 1.411) than that of Boots (in the 
baseline), all other factors being equal. The DocRes for Vitus pharmacy (VAP) was not 
significantly different from the reference, except for 2010 (OR: 0.855). Ditt Apotek (DAP) 
did not score significant as a factor at all. The DocRes reported by the independent 




though. Pharmacy chain identity as a variable is a potentially influential factor of the level of 
DocRes. 
 
Level of centralization 
The big variation in DocRes and its consistency presented in the descriptive part of the 
analysis, for the centralization variable, have found their confirmation in the logistic 
regression part. Regression coefficients for urban areas have scored positive and significant 
for all five periods (ORs: from 1.149 in 2010 to 1.35 in 2009) in reference to the baseline. 
Less and least centralized areas noted lower level of DocRes than the baseline category 
(smaller urban), with varied significance, however. That means that urban municipalities 
consistently report more doctors’ reservations than the remaining municipalities and there is a 
clear correlation between the two variables here. 
 
Pharmaceutical group 
The influence of type of pharmaceutical have proved to be significant and very stable in the 
regression analysis. The acid – modifying drugs (antiacid) represent higher level of DocRes in 
four out of five analyzed periods (OR: from 3.516 in 2007 to 5.535 in 2010) in relation to the 
reference groups (statins), all other factors being equal. Significant effects, but with a 
changing direction is noted for antidepressants. One can conclude that identity of a 
pharmaceutical, and its area of action plays an important role in prescribing preferences. 
 
6.3 Limitations and strengths of the analyses 
Due to the use of a logistic regression, the dependent variable as well as many of the 
categorical variables had to be changed into binary coding. For the DocRes this meant that 
regardless of the individual value of the proportion (whether it was 0.001 or 1), they were 




As the effect of the underlying binominal distribution, the parameters of such a model cannot 
be estimated in exactly the same way as for simple linear regression. Instead, the parameters 
are usually estimated using the method of maximum likelihood (Bewick et al. 2005). 
Although all the models built for individual years scored as significant, the average achieved 
R square values (Cox and Snell’s as well as Nagelkerke’s) were at the level of 0.1 and did not 
exceed 0.17 (see the tables in appendix), suggesting that the model is not very useful in 
predicting whether the doctors will make a reservation note on prescription or not. Although 
the contribution of many of the explanatory variables in the prediction of DocRes is 
statistically significant, the effect size is restricted.  
It has been also noted that there might have been problems with the dataset for 2008, which 
remained unexplained. Although the results for that year were not contradictory with findings 
for remaining periods, knowledge of possible reasons for data aberrations would have added 
some value to the analyses. 
Despite of these disadvantages, the present study presents a simple method to track and 
measure potential explanatory power for a number of independent variables. The use of 
descriptive statistics provides a clear introduction into the discussed problems. In the situation 
where normality of distribution of the variables cannot be assumed, the use of logistic 
regression provided means for modeling the dependence of a binary response on explanatory 
variables, not restricted to linear effects. In addition, the large sample sizes can ensure that 












7. CONCLUSIONS AND DISCUSSION 
 
The results from the present study suggest that the main hypothesis about direct impact of the 
price difference between branded and generic versions of pharmaceuticals on the doctors’ 
reservations level remains unsupported. The association between the two variables proved 
neither strong nor consistent. That suggests that economical motives of patients do not incline 
their doctors to guard against substitution. At the patient’s level, it is not the price difference, 
which prompts them to convincing their doctors to make a reservation. The earlier study by 
Dalen and colleagues (Dalen et al. 2011) concluded that the difference in prices does matter 
when it comes to generic vs. brand name prescribing, ie. the bigger the difference the more 
likely that  generic version is prescribed. However this effect applied to prescription drugs in 
general. In the same study, the type of prescription (reimbursable vs. non-reimbursable) 
proved to have a strong impact: patient with reimbursable drugs were more likely to end up 
with brand name versions.  
Compiling the findings of this thesis with the study by Dalen et al. (2011), one can draw a 
common conclusion that for the patients who are indifferent to the brand of their medication, 
the price is an important factor of their final choice and they are more likely to accept generic 
substitution.  However, to those patients, as well as their doctors, who have developed strong 
preferences towards brand name products, there are other important factors, which influence 
the decision on opposing substitution with generics, rather than the price difference. 
The performed analysis found strong and consistent association between centralization and 
doctors’ reservation levels. Urban and smaller urban municipalities show increased doctors’ 
reservation levels when compared with smaller/more remote centers. These findings confirm 
increased patients’ power triggered by stronger competition among GPs in bigger centers. 
They are also in line with the opinions of the focus group doctors’: 
"Patients in cities are more aware of their choice possibilities"- says one doctor. Another one 
adds: 
"Before I started practicing in Oslo, I was a doctor in the province. And there is a big 




cessation and so on. So when you live in Oslo, you are clearer about what you want from your 
doctor. I want this, I want that. They know which medicine they want to have and they tell 
their doctor. I want this and this. So we (doctors) have to be bit more service oriented here (in 
Oslo)." 
Others add:  
"It is expected, that it’s us (doctors) who take the decision (about the reservation note) 
according to our rules. But it doesn’t work like this with these patients. They in fact are the 
ones that decide." 
"It is often the patients who ask for it (the reservation note). They (the patients) have been to 
the pharmacy, where they got the information on the substitution, they become anxious about 
the effectiveness and side-effects, get the information from the pharmacist that their doctor 
can just write a note on the prescription, and this way they get the original drug. Later, they 
come to their doctor, with such an order in mind and it is difficult to turn it down. At least I 
don’t use that much time on it. They say “in the pharmacy they told me that you can just write 
the note”. 
Another possible explanation (as suggested by Dr. Bjørg Nitteberg Sørensen, NoMA), is that 
doctors in more central areas are influenced by contact with the pharmaceutical industry to a 
much higher degree, than in more dispersed parts of the country. They take part in more 
meetings and seminars arranged by pharmaceutical companies, and are more often visited by 
the companies’ representatives. Specialists in big university hospitals (located in big cities) 
also receive a special attention from the pharmaceutical industry, and their acquired attitude 
towards original or generic medicines can easily spread from the hospital environment to the 
primary health care level along with the first prescription. 
Yet another interesting aspect of the centralization level importance is that the role of 
pharmacies is different in less urbanized areas than big cities. The observation was raised both 
by the focus group doctors and the pharmacy wholesalers’ representatives. The respondents 
from both groups agreed that the flow of information between doctors, pharmacies and 
patients is better in smaller centers. Pharmacies have more contact with doctors; in cases of 




assortments of local pharmacies, so the cooperation between all involved parties goes more 
smoothly.  
As described by one of the doctors: “The pharmacists in rural areas know the patients as well 
as their doctors, they can offer more individualized information. The doctor knows that Mrs. 
Hansen gets usually the green pills and knows that Mrs.Larsen from the pharmacy knows it as 
well." 
The focus group doctors think that the difference is also down to the time pharmacists 
dedicate to individual patients: ”They have more time for the patients", "The patients in small 
pharmacies get better information and better service". However, the pharmacies` 
representatives did not confirm that, claiming that there was no difference in service time 
across pharmacies in more or less urbanized areas. 
When it comes to the pharmacy chain identity as an influential factor modulating doctors` 
reservation level, the obtained results are in line with the earlier study by Dalen et al. (2011), 
which discovered that pharmacy efforts are important in convincing patients to accept generic 
substitution. The authors argued that the input from pharmacy personnel on promoting 
particular products is strongly influenced by economical incentives, strictly pharmacy 
margins, which are affected by procurement prices and varied among different pharmacy 
chains. This would explain why some pharmacy chains report higher levels of patient 
reservation against generic substitutions than others do.  
The focus group doctors agreed that a strong decision power lies with the pharmacies; this is 
where the actual substitution takes place and where the patients get their information from: 
“So what the pharmacist tells the patient is also very influential. They often say to patients “if 
you react in another way to the yellow pills than to the red ones, then you have to tell your 
doctor to make a note on your prescription.” 
The present analysis found that there tends to be a significant difference when it comes to 
doctors’ reservation levels between various pharmacy chains. This difference, however, is 
dynamic in time and different pharmacy chains “score” various ranks in different periods of 
time. In theory this may be due to some pharmacies having original products as “preferred” 




chains’ representatives, Somac has been the “preferred” stepped price product for all the 
chains since the substance became part of the stepped price model (2008). One of the chains 
obtained a deal on Cipralex (in the stepped price model from March 2010). But apart from 
these, generics have been the preferred products sold at stepped price. So except for 
Cipralex/Escitalopram in 2010, the differences between the chains may not be explained by 
brand-deals held by individual pharmacy chains. Despite the variation in policies and deals, 
the representatives claim that the resulting differences in doctors’ reservation levels have no 
deeper meaning. All the chains operate in one small market, uniform surroundings, the same 
regulation system, they respond to the same third party payer (NIS), they overall have similar 
policies, and they all take part in the generic substitution scheme.  
Another variable, which turned out to be an important predictor of variation in doctors’ 
reservation level, is pharmaceutical group. Acid-modifying drugs show consistently the 
highest level of doctors’ reservations when compared with the two other selected 
pharmaceutical groups. One of the underlying reasons can be that effectiveness of this group 
of drugs is more observable to patients than that of statins.  
Another factor causing variation here can be external regulation. Since June 2005, 
Simvastatin is the “preferred medicine” or the drug of choice for all new and old statin users.  
What about the dramatic differences among different drugs from the same groups of drugs? 
The variation in doctors’ reservation levels can be very big, for example, Omeprazole: as high 
as 40% vs. Ranitidine – less than 1%, or Paroxetin – 14% vs. Escitalopram -3-4% (for more 
examples see the table  14. in the Chapter 6. 
In single cases, the fact that some original versions of medicines are available at the stepped-
price (Pantoprazol - Somac, see Table 14.), results in low reservation levels, since there is no 
practical need for it. For these cases the real preferences may remain veiled and non-reflected 
in the data on reservations. 
The doctors from the focus group admit that prescribing habits play a dominant role: 
“One hasn’t got the whole catalogue in the head. The habit is strong. The doctor does not 




“Once I have written the prescription, I don’t use any more time on it. It’s very rare that I 
remember to inform the patient that they can be dispensed a preparation with a different 
name, but it’s ok. I must admit I rarely do that.” 
They also think that the history of the pharmaceutical product very often influences the 
prescription decisions: 
“The medicines which are first in the market, which people are accustomed to for years. The 
ones that came later, they are more indifferent to. It can be also that there is a real 
difference.” 
“In many cases these other drugs have been tried out before”.  
In some doctors’ opinion there are simply differences in how various preparations work: 
“It often happens, like for example for Pravachol, that those medicines which are more rarely 
prescribed, tend to be more prompt to have reservation. If you decide for Pravachol, you want 
a concrete brand and there is a reason behind it.” 
This would indicate that some pharmaceuticals have higher rates due to their clinical 
specification. Pravastatine (original Pravachol), has a higher reservation rate, as explained by 
Dr. Steinar Madsen (NoMA), as it is more often prescribed to patients with particular 
problems with reactions to pharmaceuticals, for example patients after transplantations or 
patients receiving very many medicines (possible interactions). 
Apart from the variables – predictors tested in the thesis, the interviewed doctors indicated 
many other reasons behind variation in doctors’ reservation levels. Most often they were 
referring to patients’ characteristics, like age, and ethnicity, which confirms the finding of 
other recent Norwegian studies on generic substitution (Dalen et al. 2011; Håkonsen and 
Toverud 2011). Here are some of the opinions: 
“What is often the big problem are the immigrant patients, who don’t understand or 
misunderstand the information. They make me personally write the note on the prescription to 
make sure they follow my information correctly; or the elderly who misunderstand. They get 




boxes at home with different names on them, so they end up taking both medicines. It does 
happen quite a lot.” 
“For elderly patients I always write the note against substitution. But we don’t know always 
about those medicines which have generic counterparts, we don’t know the names, so I feel I 
have no control over this”. 
In the opinion of the pharmacy chains’ representatives, the absence or presence of a 
reservation note is sometimes a question of doctors’ characteristics or simply of the computer 
system they use for prescription. They gave examples that at some practices the reservation 
note is set as default function. 
Summarizing, the quest for factors that influence doctors to guard against generic substitution 
remains unexhausted, and the model presented in this thesis can be expanded. Disaggregating 
the used dataset to a more individual level is, unfortunately, not possible (since the pharmacy 
reservation data report presents aggregated figures at monthly level), however, adding new 
data on, for example, marketing expenditure of pharmaceutical companies, could help explore 
the influence of marketing directed to doctors.  
A well functioning generic substitution system is in the interest of a healthy pharmaceutical 
market, as well as individual patients, and the society in general. One of the focus group 
doctors concluded: 
“I don’t think there is a big problem with it now. When it started it was terrible. All patients 
were asking about it. There was lots of confusion. Now, I think, most are used to the system.” 
It seems that in the Norwegian setting, after a decade in use, despite some challenges, it can 










i Legemiddelindustrien “Tall og Fakta 2011” (The Association of the Pharmaceutical Industry 
in Norway, “Facts and figures 2011”) 
http://www.lmi.no/media/1197884/tall-og-fakta-2011_web.pdf 
ii
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ATC code Mean N Std. Deviation 
antiacid .081026 12893659 .2549090 
statins .041353 42401205 .1615336 
antidepressant .049963 16547608 .1941429 
Total .050457 71842471 .1896315 
 
DocRes  * Årmåned 
DocRes 
Årmåned Mean N Std. Deviation 
2006 .054322 10991001 .1852413 
2007 .058670 13301872 .1857367 
2008 .029311 14407609 .1594259 
2009 .053580 15823968 .2008030 
2010 .056432 17318021 .2059994 





Byttegruppekode Mean N Std. Deviation 
000012 .012260 241030 .0708390 
000013 .007881 908240 .0499617 
000014 .008980 882767 .0640786 
000015 .008559 247110 .0630494 
000023 .443703 94712 .4721963 
000024 .253050 3728880 .4095786 
000028 .006310 3613077 .0464592 
000251 .034814 1167018 .1398985 
000252 .030982 11487964 .1239552 
000253 .030665 22329936 .1285401 
000254 .045825 4347756 .1759167 
000261 .142611 751088 .3326664 




000657 .102912 4329509 .2879979 
000658 .002855 68644 .0376766 
000661 .108596 2612951 .2658982 
000671 .006982 8676998 .0504770 
000853 .157835 2317443 .3459432 
000938 .004009 259955 .0436223 
001420 .005920 2282408 .0237778 
001525 .002516 635480 .0218830 
001651 .027079 94021 .0885483 
001652 .039062 558400 .1399809 




Kjedekode Mean N Std. Deviation 
AP1 .049588 31890722 .1875571 
VAP .049281 18648891 .1901165 
BAP .055426 15778251 .1955412 
DAP .046106 3175139 .1822430 
UDA .044085 2349468 .1824603 





Sentralitet Mean N Std. Deviation 
urban .054073 46312851 .1944655 
smaller urban .048073 13455968 .1841961 
less centralized .035967 5215467 .1630188 
least centralized .041728 6858186 .1849599 




Sentralitet Årmåned Mean N Std. Deviation 
urban 2006 .056591 7236089 .1852025 
2007 .060550 8624778 .1861770 
2008 .032014 9300829 .1665034 
2009 .059332 10227511 .2099051 




Total .054073 46312851 .1944655 
smaller urban 2006 .053615 2121344 .1846403 
2007 .060786 2551176 .1889100 
2008 .025831 2625788 .1478110 
2009 .047555 2830487 .1886083 
2010 .052785 3327173 .2001328 
Total .048073 13455968 .1841961 
less centralized 2006 .045410 667197 .1788733 
2007 .044734 958176 .1682725 
2008 .020954 1057778 .1332337 
2009 .034117 1197552 .1584702 
2010 .038511 1334764 .1750232 
Total .035967 5215467 .1630188 
least centralized 2006 .045039 966370 .1906047 
2007 .051595 1167743 .1884648 
2008 .024278 1423214 .1499175 
2009 .041809 1568419 .1881985 
2010 .047493 1732440 .2008395 
Total .041728 6858186 .1849599 
Total 2006 .054322 10991001 .1852413 
2007 .058670 13301872 .1857367 
2008 .029311 14407609 .1594259 
2009 .053580 15823968 .2008030 
2010 .056432 17318021 .2059994 




Kjedekode Årmåned Mean N Std. Deviation 
AP1 2006 .057787 4941399 .1915239 
2007 .057650 5931835 .1918190 
2008 .029732 6138966 .1577723 
2009 .053405 7108164 .1925706 
2010 .050415 7770359 .1973627 
Total .049588 31890722 .1875571 
VAP 2006 .042868 2447963 .1561272 
2007 .055113 3148459 .1831119 




2009 .051675 4144829 .2050334 
2010 .062152 4877460 .2124945 
Total .049281 18648891 .1901165 
BAP 2006 .061607 2586225 .2024367 
2007 .067867 3105186 .1794115 
2008 .028236 3251764 .1570307 
2009 .059470 3398521 .2153338 
2010 .061261 3436554 .2133606 
Total .055426 15778251 .1955412 
DAP 2006 .048266 750396 .1715288 
2007 .054701 733059 .1846422 
2008 .026807 528710 .1546739 
2009 .042910 550344 .1870314 
2010 .052704 612630 .2067888 
Total .046106 3175139 .1822430 
UDA 2006 .041577 265017 .1689983 
2007 .036736 383334 .1583748 
2008 .023035 457989 .1372825 
2009 .045542 622111 .1928687 
2010 .063756 621017 .2153282 
Total .044085 2349468 .1824603 
Total 2006 .054322 10991001 .1852413 
2007 .058670 13301872 .1857367 
2008 .029311 14407609 .1594259 
2009 .053580 15823968 .2008030 
2010 .056432 17318021 .2059994 




ATC code Årmåned Mean N Std. Deviation 
antiacid 2006 .085882 1590487 .2550245 
2007 .109488 1939262 .2868228 
2008 .079538 2650000 .2541906 
2009 .076384 3155422 .2527151 
2010 .068570 3558488 .2369864 
Total .081026 12893659 .2549090 




2007 .051391 7946062 .1476079 
2008 .010693 8696691 .0983950 
2009 .047154 9582374 .1796820 
2010 .050696 9846710 .1972459 
Total .041353 42401205 .1615336 
antidepressant 2006 .051905 3071146 .2022573 
2007 .046753 3416548 .1876522 
2008 .038726 3060918 .1814695 
2009 .050219 3086173 .2013240 
2010 .059829 3912823 .1964855 
Total .049963 16547608 .1941429 
Total 2006 .054322 10991001 .1852413 
2007 .058670 13301872 .1857367 
2008 .029311 14407609 .1594259 
2009 .053580 15823968 .2008030 
2010 .056432 17318021 .2059994 





ATC code Årmåned Mean N Std. Deviation 
antiacid 2006 4.955367 1590487 2.9791950 
2007 4.785560 1939262 3.1563654 
2008 266.774853 2650000 1.1378325E3 
2009 243.671882 3155422 1.0774606E3 
2010 212.376837 3558488 957.0227647 
Total 174.406903 12893659 902.3131920 
statins 2006 .537813 6329368 1.5373120 
2007 .470019 7946062 1.6213917 
2008 .366328 8696691 1.4291378 
2009 2.908735 9582374 .9399797 
2010 2.278817 9846710 .9757085 
Total 1.430056 42401205 1.6941616 
antidepressant 2006 2.398271 3071146 1.1302770 
2007 2.409526 3416548 1.3260146 
2008 2.566647 3060918 1.1249917 




2010 2.297510 3912823 .8988233 
Total 2.442567 16547608 1.0845243 
Total 2006 1.696925 10991001 2.3344990 
2007 1.597333 13301872 2.4258956 
2008 49.834462 14407609 498.7360349 
2009 50.855447 15823968 490.6704602 
2010 45.453747 17318021 442.0444246 
Total 32.707641 71842471 387.9610964 
 
 
PASW output - Binary logistic regression 
 
1. Output for binary logistic regression for the year 2006 only. Baseline: smaller urban 
Boots pharmacy, reservation level for statins. 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 521.118 10 .000 
Block 521.118 10 .000 
Model 521.118 10 .000 
 
Chi-square and Sig. - This is the chi-square statistic and its significance level. The value 
given in the Sig. column is the probability of obtaining the chi-square statistic given that the 
null hypothesis is true.  In other words, this is the probability of obtaining this chi-square 
statistic (521.118) if there is in fact no effect of the independent variables, taken together, on 
the dependent variable.  This is, of course, the p-value, which is compared to a critical value, 
perhaps .05 or .01 to determine if the overall model is statistically significant.  In this case, the 












 .048 .074 
a. Estimation terminated at iteration number 5 because 











 Selected Casesa Unselected Casesb 
 BinaryDocRes Percentage 
Correct 
BinaryDocRes Percentage 
Correct  .00 1.00 .00 1.00 
Step 1 BinaryDocRes .00 8325 5 99.9 43211 2379 94.8 
1.00 2305 2 .1 10240 22 .2 
Overall Percentage   78.3   77.4 
a. Selected cases Årmåned EQ 1 
b. Unselected cases Årmåned NE 1 
c. The cut value is ,500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Delta .070 .009 63.190 1 .000 1.073 
urban(1) .191 .060 10.035 1 .002 1.210 
less_centralized(1) -.191 .103 3.406 1 .065 .826 
least_centralized(1) -.199 .086 5.305 1 .021 .820 
AP1(1) -.260 .063 17.168 1 .000 .771 
VAP(1) -.043 .075 .334 1 .563 .958 
DAP(1) -.100 .102 .973 1 .324 .905 
OTHER(1) -.265 .148 3.235 1 .072 .767 
antiacid(1) 1.263 .063 403.116 1 .000 3.535 
antidepressants(1) .757 .061 156.185 1 .000 2.132 
Constant -2.180 .120 327.324 1 .000 .113 





2. Output for binary logistic regression for the year 2007 only. Baseline: smaller urban 
Boots pharmacy, reservation level for statins. 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 




Block 622.742 10 .000 













 .049 .075 
a. Estimation terminated at iteration number 5 because 





Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Delta .036 .007 25.782 1 .000 1.037 
urban(1) .218 .056 15.139 1 .000 1.244 
less_centralized(1) -.071 .091 .615 1 .433 .931 
least_centralized(1) -.229 .082 7.896 1 .005 .795 
AP1(1) -.155 .058 7.071 1 .008 .856 
VAP(1) -.019 .065 .085 1 .771 .981 
DAP(1) .044 .093 .217 1 .641 1.045 
OTHER(1) -.348 .128 7.443 1 .006 .706 
antiacid(1) 1.257 .055 513.447 1 .000 3.516 







 Selected Casesa Unselected Casesb 
 BinaryDocRes Percentage 
Correct 
BinaryDocRes Percentage 
Correct  .00 1.00 .00 1.00 
Step 1 BinaryDocRes .00 9564 0 100.0 42032 2324 94.8 
1.00 2748 0 .0 9812 9 .1 
Overall Percentage   77.7   77.6 
a. Selected cases Årmåned EQ 2 
b. Unselected cases Årmåned NE 2 




Constant -1.966 .107 335.701 1 .000 .140 





3. Output for binary logistic regression for the year 2008 only. Baseline: smaller urban 
Boots pharmacy, reservation level for statins. 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 363.313 10 .000 
Block 363.313 10 .000 













 .027 .052 
a. Estimation terminated at iteration number 5 because 
parameter estimates changed by less than ,001. 
 







 Selected Casesa Unselected Casesb 
 BinaryDocRes Percentage 
Correct 
BinaryDocRes Percentage 
Correct  .00 1.00 .00 1.00 
Step 1 BinaryDocRes .00 11754 0 100.0 42166 0 100.0 
1.00 1597 0 .0 10972 0 .0 
Overall Percentage   88.0   79.4 
a. Selected cases Årmåned EQ 3 
b. Unselected cases Årmåned NE 3 




 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Delta .000 .000 38.878 1 .000 1.000 
urban(1) .193 .069 7.871 1 .005 1.212 
less_centralized(1) -.208 .114 3.351 1 .067 .812 
least_centralized(1) -.271 .100 7.337 1 .007 .762 
AP1(1) .344 .072 23.102 1 .000 1.411 
VAP(1) .050 .080 .394 1 .530 1.052 
DAP(1) -.176 .136 1.677 1 .195 .838 
OTHER(1) -.163 .152 1.145 1 .285 .850 
antiacid(1) -.303 .067 20.606 1 .000 .739 
antidepressants(1) -.492 .069 50.901 1 .000 .612 
Constant -2.192 .130 286.589 1 .000 .112 






4. Output for binary logistic regression for the year 2009 only. Baseline: smaller urban 
Boots pharmacy, reservation level for statins. 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1535.392 10 .000 
Block 1535.392 10 .000 













 .105 .168 
a. Estimation terminated at iteration number 5 because 





Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Delta -.001 .000 24.798 1 .000 .999 
urban(1) .300 .059 25.770 1 .000 1.350 
less_centralized(1) -.054 .094 .333 1 .564 .947 
least_centralized(1) -.133 .082 2.647 1 .104 .876 
AP1(1) -.415 .062 45.128 1 .000 .660 
VAP(1) -.072 .069 1.075 1 .300 .931 
DAP(1) -.145 .116 1.571 1 .210 .865 
OTHER(1) -.304 .117 6.790 1 .009 .738 
antiacid(1) 1.707 .055 958.223 1 .000 5.513 
antidepressants(1) .703 .055 161.997 1 .000 2.020 
Constant -1.995 .107 347.141 1 .000 .136 
a. Variable(s) entered on step 1: Delta, urban, less_centralized, least_centralized, AP1, VAP, DAP, OTHER, 
antiacid, antidepressants. 
 
5. Output for binary logistic regression for the year 2010 only. Baseline: smaller urban 
Boots pharmacy, reservation level for statins. 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1651.652 10 .000 
Block 1651.652 10 .000 








 Selected Casesa Unselected Casesb 
 BinaryDocRes Percentage 
Correct 
BinaryDocRes Percentage 
Correct  .00 1.00 .00 1.00 
Step 1 BinaryDocRes .00 11232 0 100.0 42688 0 100.0 
1.00 2665 0 .0 9904 0 .0 
Overall Percentage   80.8   81.2 
a. Selected cases Årmåned EQ 4 
b. Unselected cases Årmåned NE 4 















 .096 .153 
a. Estimation terminated at iteration number 5 because 





Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Delta -.001 .000 24.898 1 .000 .999 
urban(1) .139 .052 7.154 1 .007 1.149 
less_centralized(1) -.251 .087 8.420 1 .004 .778 
least_centralized(1) -.196 .072 7.482 1 .006 .822 
AP1(1) -.140 .057 6.082 1 .014 .869 
VAP(1) -.157 .059 7.104 1 .008 .855 
DAP(1) -.176 .099 3.134 1 .077 .839 
OTHER(1) -.106 .098 1.178 1 .278 .899 
antiacid(1) 1.711 .052 1071.697 1 .000 5.535 
antidepressants(1) .612 .048 163.595 1 .000 1.845 
Constant -1.947 .093 440.687 1 .000 .143 








 Selected Casesa Unselected Casesb 
 BinaryDocRes Percentage 
Correct 
BinaryDocRes Percentage 
Correct  .00 1.00 .00 1.00 
Step 1 BinaryDocRes .00 13040 0 100.0 40880 0 100.0 
1.00 3252 0 .0 9317 0 .0 
Overall Percentage   80.0   81.4 
a. Selected cases Årmåned EQ 5 
b. Unselected cases Årmåned NE 5 



















Appendix 2 Selected substitution groups 
 Table 19. Substitution groups selected for the analyses
ATCcode ATCname 
S.Group 
number Substitution group name  DDDq  DDDunit 
A02BA02 RANITIDINE 000012 RANITIDIN BRUSETABLETTER 150MG*      0,300  G 
A02BA02 RANITIDINE 000013 RANITIDIN TABLETTER 150MG      0,300  G 
A02BA02 RANITIDINE 000014 RANITIDIN TABLETTER 300MG      0,300  G 
A02BA02 RANITIDINE 000015 RANITIDIN BRUSETABLETTER 300MG      0,300  G 
A02BC01 OMEPRAZOLE 000023 OMEPRAZOL TABLETTER 10MG**    20,000  MG 
A02BC01 OMEPRAZOLE 000024 OMEPRAZOL TABLETTER 20MG    20,000  MG 
A02BC02 PANTOPRAZOLE 001420 PANTOPRAZOL ENTEROTABLETTER 40 MG****      0,040  G 
A02BC02 PANTOPRAZOLE 001525 PANTOPRAZOL ENTEROTABLETTER 20 MG****      0,040  G 
A02BC03 LANSOPRAZOLE 000028 LANSOPRAZOL ENTEROKAPSLER 30MG***      0,030  G 
A02BC03 LANSOPRAZOLE 000938 LANSOPRAZOL ENTEROKAPSLER 15MG***      0,030  G 
C10AA01 SIMVASTATIN 000251 SIMVASTATIN TABLETTER 10MG      0,030  G 
C10AA01 SIMVASTATIN 000252 SIMVASTATIN TABLETTER 20MG      0,030  G 
C10AA01 SIMVASTATIN 000253 SIMVASTATIN TABLETTER 40MG      0,030  G 
C10AA01 SIMVASTATIN 000254 SIMVASTATIN TABLETTER 80MG      0,030  G 
C10AA03 PRAVASTATIN 000261 PRAVASTATIN TABLETTER 20MG      0,030  G 
C10AA03 PRAVASTATIN 000853 PRAVASTATIN TABLETTER 40MG      0,030  G 
N06AB04 CITALOPRAM 000656 CITALOPRAM TABLETTER 10MG      0,020  G 
N06AB04 CITALOPRAM 000657 CITALOPRAM TABLETTER 20MG      0,020  G 
N06AB04 CITALOPRAM 000658 CITALOPRAM TABLETTER 40MG      0,020  G 
N06AB05 PAROXETINE 000661 PAROKSETIN TABLETTER 20MG    20,000  MG 
N06AB10 ESCITALOPRAM 000671 ESCITALOPRAM TABLETTER 10MG*****    10,000  MG 
N06AB10 ESCITALOPRAM 001651 ESCITALOPRAM TABLETTER 5MG*****    10,000  MG 




*Only original has been available on the market 
**Usually prescribed to children 
*** Original not available on the market 
****Original (Somac) available at stepped price at all pharmacy chains 
***** Original (Cipralex) available at stepped price at one of the pharmacy chains in 2010 
